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Chapter 1
Introduction
M. Suker, C.H.J. van Eijck 
Adapted from book chapter ‘Pancreatic resection after neoadjuvant treatment’. Published 
in: ‘Minimally Invasive Surgery for Upper Abdominal Cancer’. Springer International 
Publishing; 2017. p. 221-229. 
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Introduction
Pancreatic cancer has a very poor prognosis, with the projection to be the second 
leading cancer-related death in 2030.[1] Pancreatic cancer can be divided in three 
stages: resectable (15%), locally advanced (35%), and metastatic disease (50%).[2]
The diagnosis of resectable and locally advanced pancreatic cancer is determined 
by the tumor invasion of critical structures, in particular the portal vein, superior 
mesenteric vein, coeliac artery, and superior mesenteric artery. This tumor invasion 
is usually assessed by contrast enhanced computed tomography (CT). There are 
several definitions for resectable and locally advanced disease, usually based on the 
tumor burden of the surrounding major vessels. This tumor burden can be defined 
as no invasion at all to the surrounding structures (resectable disease) or too much 
invasion in the surrounding structures to be deemed resectable (locally advanced 
disease). In between these two extremes, there is a diagnostic gap where a tumor has 
some vessel involvement but is still resectable, this gap is called borderline resectable 
disease. The two most commonly used definitions for (borderline) resectable disease 
and locally advanced disease are that of National Comprehensive Cancer (NCCN) and 
the combined definition of Americas Hepato-Pancreato-Biliary Association (AHPBA), 
the Society of Surgical Oncology (SSO), and the Society for Surgery of the Alimentary 
Tract (SSAT).[3, 4] In the Netherlands, the Dutch Pancreatic Cancer Group uses it owns 
definition to determine resectability.[5] The definitions of NCCN, AHPBA/SSO/SSAT, 
and DPCG for borderline resectable and locally advanced disease are summarized 
in Table 1. For decades, the primary treatment for borderline resectable pancreatic 
cancer was upfront surgery. However, neoadjuvant therapy is becoming more and 
more a valuable upfront therapy for borderline resectable disease. Although there 
is no clear level I evidence for this treatment.[6] The main purpose of neoadjuvant 
treatment is threefold: 1) improve probability of radical resection, 2) patient selection 
of patients with rapid disease progression that will undergo unnecessary surgery, 
3) early treatment of occult metastasis. As a result, more patients receive systemic 
treatment, since a significant portion of patients are not eligible for adjuvant therapy 
due to morbidity.[7] In contrary, locally advanced pancreatic cancer is conventionally 
treated with induction chemotherapy and sometimes followed by local therapy such 
as (chemo)radiotherapy or local ablation. Surgery is not recommended as an upfront 
treatment in locally advanced unresectable pancreatic cancer and is only reserved for 
patients with disease response and after tumor downstaging with chemotherapy and 
or (chemo)radiotherapy.[8] 
 In this thesis, we focus on patients diagnosed with locally advanced pancreatic 
cancer and will be discussed in more depth in the next paragraph. 
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1Table 1. NCCN, AHPBA/SSO/SSAT, and DPCG definitions of borderline resectable and locally advanced pancreatic cancer. 
NCCN AHPBA/SSO/SSAT DPCG
Borderline 
resectable
No distant metastases No distant metastasis No distant metastasis
Solid tumor contact with SMA < 180 
degrees
Solid tumor contact with SMA < 
180 degrees
Solid tumor contact with SMA  
< 90 degrees
Solid tumor contact with GA and/or CHA 
without involvement of CA 
Solid tumor contact with 
GA and/or CHA without 
involvement of CA
Solid tumor contact with CA or CHA  
< 90 degrees
Reconstructable SMV and/or PV despite 
tumor involvement or occlusion
Reconstructable SMV and/or PV 
despite tumor involvement or 
occlusion without tumor contact 
with surrounding arteries
Solid tumor contact with SMV or PV  
< 270 degrees
Locally 
advanced
No distant metastasis No distant metastasis No distant metastasis
Solid tumor contact with SMA and/or CA 
>180 degrees
Circumferential encasement of 
SMA and/or CHA
Solid tumor contact with CA or CHA  
≥ 90 degrees
Solid tumor contact with the first jejunal 
SMA branch and/or aortic involvement. 
Abutment of CA due to tumor 
involvement
Solid tumor contact with SMV or PV  
≥ 270 degrees
Unreconstructable SMV and/or PV due to 
tumor involvement or occlusion
Unreconstructable SMV and/or 
PV due to tumor involvement or 
occlusion
Contact with most proximal draining 
jenjunal branch in to SMV.
SMA: Superior Mesenteric Artery
GA: gastroduodenal artery
CA: Coeliac Axis
CHA: Common Hepatic Artery
SMV: Superior Mesenteric Vein
PV: Portal Vein
Locally advanced pancreatic cancer
The diagnosis of borderline resectable pancreatic cancer remains difficult. There are 
some consensus definitions (Table 1). Bottom line, borderline resectable pancreatic 
cancer is diagnosed by the surgeon if he deems the tumor resectable despite vascular 
encasement on CT-scan with a possibility, that the resection is radical and resected 
vascular structures are reconstructable. The diagnosis of locally advanced pancreatic 
cancer (LAPC) is a more defined diagnosis. The tumor has a vascular invasive 
aspect on CT-scan, making it unresectable due to the high probability of micro- or 
macroscopically irradical resection. Unfortunately, there is no worldwide consensus 
on how much the vascular involvement is, to deem the tumor unresectable (Table 1). 
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Part I: Staging of LAPC
The diagnostic approach of LAPC patients consists of a CT-scan of chest, abdomen, 
and pelvis to exclude metastatic disease.[7] Although, in (borderline) resectable 
pancreatic cancer chest CT-scans are recommended, many centers do no perform 
them routinely.[9] This is due to the limited influence of these scans on treatment 
management and survival.[10, 11] In LAPC, the clinical value of chest CT-scans is 
not yet defined as there is limited data available on this matter. Further staging of 
LAPC can be accomplished by staging laparoscopy. It is recommended to perform 
a staging laparoscopy in LAPC, if in any phase of the treatment a local therapy is 
considered (i.e. radiotherapy or surgery).[4] A staging laparoscopy has shown to 
upstage approximately one third of the patients with LAPC on CT-scan to a metastatic 
disease.[12, 13] However, these studies are more than a decade old and should be 
interpreted with caution, due to the more accurate imaging techniques nowadays. 
Therefore, contemporary studies are warranted. 
Part II: Treatment of LAPC
Conventionally, LAPC is treated like metastatic disease with induction systemic 
chemotherapy. For decades, fluorouracil was the standard first-line treatment for 
LAPC. This changed after an RCT in 1997, including patients with metastatic and 
locally advanced pancreatic cancer, which showed a median overall survival (OS) of 
5.6 months in the gemcitabine arm while fluorouracil arm gave a median OS of 4.4 
months (p=0.0025).[14] More recently, an RCT was conducted by Conroy et al. in 2011 
with FOLFIRINOX versus gemcitabine for patients with metastatic and LAPC.[15] The 
median OS in the FOLFIRINOX group was 11.1 versus 6.8 months in the gemcitabine 
group (p<0.001). Since this revolutionary paper, many case series with first-line 
FOLFIRINOX for LAPC are published. Recently, a phase II trial endorsed the potential 
survival benefit of first-line FOLFIRINOX for patients with LAPC. In 31 patients, the 
median OS was 26.6 months, where 42% of the patients underwent a resection, 
all being a radical resection.[16] Another systemic chemotherapy regimen is nab-
paclitaxel–gemcitabine and is examined in a recent RCT from Von Hoff et al. Although 
including only patients with metastatic pancreatic cancer, this RCT showed a survival 
benefit for nab-paclitaxel–gemcitabine versus gemcitabine alone (median OS 8.5 
vs. 6.7 months, p <0.001).[17] The benefit of systematic therapy above surgery-first 
approach in patients with LAPC was further underlined in an American nationwide 
database set which showed a median OS of 21 months (n=377) versus 14 months 
(n=216) in favor of the neoadjuvant group (p<0.001).[18] 
 Additional treatment after first-line chemotherapy is only advised if there is no 
clinical tumor progression. The optimal subsequent regimen has yet to be established, 
due to contradicting results. In the last decade, there were three randomized trials that 
13
1evaluated the effect of (chemo)radiotherapy versus chemotherapy alone in LAPC.[7]One study randomized gemcitabine (n=60) versus fluorouracil-cisplatin-radiotherapy 
followed by gemcitabine (n=59), and showed a median OS of 14.3 months versus 8.4 
months in favor of the gemcitabine alone arm (p= 0.014). In the contrary, another 
study randomized between gemcitabine versus gemcitabine-radiotherapy, and 
reported a median OS of 9.2 months versus 11.1 months in favor of the gemcitabine-
radiotherapy arm (p=0.017). The most recent study that was published showed no 
difference in subsequent treatment with radiotherapy. This study enrolled patients 
with LAPC for 4 months of gemcitabine with or without erlotinib. If no progression 
was seen, the patients were randomized between 2 months extension (n=136) of 
the chemotherapy or capecitabine-radiotherapy (n=133) (median OS 15.2 vs 16.5, 
p = 0.83). Less is known about the survival benefit of resection after induction 
chemotherapy and radiotherapy. Currently, there is no consensus in the literature on 
selection of patients with LAPC for resection after induction therapy.[19] 
Outline of this thesis
The staging of LAPC remains essential, especially in the current expansion of local 
therapies.[20] As proper staging of LAPC allows for better understanding of new 
treatment protocols, since patients with understaged disease are excluded before 
diluting true outcomes. Furthermore, there are no definitive answers on which 
regimens should be used as treatment for LAPC. The role of FOLFIRINOX and 
radiotherapy in the treatment of LAPC is of interest, as they have shown promising 
results lately. This thesis is divided in two parts. The first part focuses on the staging 
of LAPC. The second part focuses on the treatment of patients with LAPC. 
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Part I: Staging of LAPC
Chapter 2 evaluates the clinical value of follow-up chest CT-scans in patients with 
LAPC. 
Chapter 3 examines the yield of staging laparoscopy for occult metastasis in LAPC. 
Part II: Treatment of LAPC
Chapter 4 is a systematic review and meta-analysis on survival data of FOLFIRINOX 
treatment in patients with LAPC. 
Chapter 5 presents the results of a patient cohort with LAPC treated with FOLFIRINOX 
in Erasmus MC.
Chapter 6 outlines the findings of a multicenter phase II trial on FOLFIIRNOX and 
stereotactic body radiotherapy for LAPC patients. 
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Abstract
Introduction:
Locally advanced pancreatic cancer (LAPC) is found in 35% of patients with pancreatic 
cancer. However, these patients often have occult metastatic disease. Patients with occult 
metastases are unlikely to benefit from locoregional treatments. This study evaluated the 
yield of occult metastases during staging laparoscopy in patients with LAPC. 
Methods:
Between January 2013 and January 2017 all patients with LAPC underwent a staging 
laparoscopy after a recent tri-phasic CT-scan of the chest and abdomen. Data were 
retrospectively reviewed from a prospectively maintained database. Univariate and 
multivariable logistic regression analysis was conducted to predict metastasis found 
at laparoscopy. 
Results:
A total of 91 (41% male, median age 64 years) LAPC patients were included. The 
median time between CT-scan and staging laparoscopy was 21 days. During staging 
laparoscopy metastases were found in 17 patients (19%, 95% CI: 12% - 28%). Seven 
(8%) patients had liver-only, 9 (10%) patients peritoneal-only, and 1 (1%) patient both 
liver and peritoneal metastases. Univariate logistic regression analysis showed that 
CEA (OR 1.056, 95% CI 1.007-1.107, p=0.02) was the only preoperative predictor for 
occult metastases. In a multivariable logistic regression analysis of the preoperative 
risk factors again only CEA was an independent predictor for occult metastatic 
disease (p=0.03). Patients with a CEA above 5 µg/L had a risk of occult metastasis 
of 91%. FOLFIRINOX was given to 69 (76%) of the patients with a median number 
of cycles of 8. Subsequent radiotherapy was given to 44 (48%) patients after the 
FOLFIRINOX treatment. Six (14%) patients underwent a resection after FOLFIRINOX 
and radiotherapy. The overall 1-year survival was 53% in patients without occult 
metastasis versus 29% with occult metastasis (p=0.11). The 1-year OS for patients 
that completed FOLFIRINOX and radiotherapy was 84%.
Conclusion:
The yield of staging laparoscopy for occult intrahepatic or peritoneal metastases in patients 
with locally advanced pancreatic cancer was 19%. Staging laparoscopy is recommended 
for patients with LAPC for accurate staging to determine optimal treatment.
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Introduction 
 Projections indicate that pancreatic cancer will be the second leading causes of 
cancer-related death by 2030.[1] At the time of diagnosis, about 15% of patients has 
(borderline) resectable disease (stage I or II), 35% locally advanced pancreatic cancer 
(LAPC, stage III), and 50% metastatic disease (stage IV).[2] The diagnosis of resectable 
disease and LAPC is determined by the extent of tumor contact with the superior 
mesenteric artery, celiac artery, superior mesenteric vein, and portal vein.[3] Several 
definitions for LAPC vary mainly in the extent of tumor contact. 
 Neoadjuvant treatment is becoming the standard treatment in patients with LAPC, 
where induction chemotherapy followed by locoregional therapy is often used.[4] 
Patients with dramatic response after neoadjuvant treatment, identified by clinical 
and radiological response without evidence for metastatic disease, are considered 
for surgery.[5] Therefore, detection of occult metastatic disease in LAPC patients is 
particularly relevant in the era of several locoregional treatments for PDAC, including 
radiofrequent ablation (RFA), irreversible electroporation (IRE), and stereotact body 
radiotherapy (SBRT).[4, 6] The assumption is that locoregional treatments are not or 
at least less effective in the presence of occult metastatic disease.
 Staging consists of a tri-phasic CT-scan of chest, abdomen, and pelvis to detect 
metastatic disease. [5] Most guidelines advice that the most recent CT scan should be 
less than 4-6 weeks old prior to start of treatment. A consensus report by the American 
Hepato-Pancreato-Biliary Association recommended staging laparoscopy in patients 
with LAPC.[7] Several studies have estimated the yield of staging laparoscopy in 
patients with LAPC at about 35%, but imaging has improved considerably in recent 
years.[8, 9]
 The aim of this study was to assess the yield of staging laparoscopy in patients 
with LAPC after recent and high-quality tri-phasic computed tomography (CT). 
Methods
Between January 2013 and January 2017 all patients with biopsy-proven LAPC and 
eligible for FOLFIRINOX were included from four hospitals. The diagnostic work-up 
included a tri-phasic CT scan and EUS with fine needle aspiration (FNA). CT-scan was 
performed on a 128 slice CT scanner with 3 phases (unenhanced, late arterial (35 sec ) 
and portal-venous (70 sec) of the upper abdomen after intravenous injection of 
contrast material. In addition, the lower abdomen and thorax were scanned in the 
last phase. LAPC was defined according to the Dutch guidelines as tumor contact 
with the superior mesenteric artery (SMA), coeliac artery, or common hepatic artery 
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exceeding 90 degrees or contact with the superior mesenteric vein or portal vein 
exceeding 270 degrees (Table 1).[10] Only patients eligible for protocolled systemic 
chemotherapy with FOLFIRINOX and subsequent radiotherapy were included.[11] 
All patients underwent a staging laparoscopy to exclude occult metastases. The 
institutional review board waived an informed consent.
Table 1. Definition of resectability according to the Dutch Pancreatic Cancer Group. 
SMA Celiac axis CHA SMV-PV
Resectable  
(all four required)
no contact no contact no contact ≤90° contact
Borderline resectable  
(minimally one required)
≤90° contact ≤90° contact ≤90° contact ≤90°-270° contact, and no occlusion
Irresectable  
(minimally one required)
contact > 90° contact > 90° contact > 90° contact > 270° or occlusion
 The staging laparoscopy was standardized in all patients and done under general 
anesthesia. The procedure started with open introduction of a 10mm trocar through 
an infraumbilical incision. The 30 degrees endoscope was inserted and the entire 
abdominal cavity was inspected. A second (and sometimes third) 5 mm trocar was 
placed in the right or left upper abdominal quadrant to evaluate the posterior aspect 
of segments 2, 3, 4, 5, and 6 of the liver, the omentum majus and minus, Douglas, 
the mesentery of the transverse colon, and Treitz’ ligament. Any suspicious lesion 
was biopsied and submitted for pathological evaluation. If occult metastasis was 
found during staging laparoscopy only systemic FOLFIRINOX chemotherapy was 
given, without radiotherapy. For the patients that did not show occult metastasis 
during staging laparoscopy, patients were re-staged by CT scan after 4 and 8 cycles of 
FOLFIRINOX chemotherapy. If no metastatic disease was found on imaging, patients 
received radiotherapy. In the period 2013 to 2015 conventional radiotherapy with 30 
fractions of 2 Gray was given, whereas between 2015 and 2017 five fractions of 8 Gray 
stereotactic body radiotherapy (SBRT) was given. After FOLFIRINOX and radiotherapy 
patients were considered for exploration and a possible resection based on the local 
extent of disease and performance status. 
 Data were collected in a prospectively maintained database, and were 
retrospectively reviewed. Additional data were collected retrospectively. The 
following parameters were retrieved: baseline characteristics including serum tumor 
markers (CEA (µg/L) and CA 19-9 (kU/L), date of CT-scan prior to laparoscopy, date of 
staging laparoscopy, length of stay, and findings during staging laparoscopy. If an 
abdominal metastasis was found in the first two months post-laparoscopy on follow-
up imaging this was calculated as a false negative rate of the staging laparoscopy. 
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 Univariate and multivariable logistic regression analysis was conducted to predict the 
presence of occult metastasis found at laparoscopy. Potential preoperative risk factors for 
occult metastatic disease included gender, age, smoking, tumor size, and serum tumor 
markers (CEA (µg/L) and CA 19-9 (kU/L)). Conventional cut-off values were used for both 
tumor markers: serum CA19-9 ≥ 35 and CEA value ≥ 5. The 1-year overall survival (OS) 
was calculated from date of histology to date of death. The survival outcomes will be 
presented using Kaplan-Maier and compared log-rank in SPSS (version 21). 
Results
From January 2013 to January 2017, 91 (41% male, median age 64 years) consecutive 
patients with biopsy-proven LAPC staged on tri-phasic CT-scan underwent a staging 
laparoscopy to exclude occult metastasis. Symptoms found at presentation were 
obstructive jaundice in 44 (48%) patients, diabetes in 24 (26%) patients, weight loss 
in 74 (81%) patients, and pain in 71 (78%) patients. The tumor location was in the 
pancreatic head in 56 (62%) patients, and pancreatic tail in 36 (38%) patients. Median 
tumor size was 37 mm [IQR 30-46]. The median time between CT-scan and staging 
laparoscopy was 21 days [IQR 12 - 32, 95% range 3 - 63]. All baseline characteristics of 
the included patients are shown in table 2.
 During staging laparoscopy, a biopsy was performed in 36 (40%) patients. In 
17 (19%) patients the biopsy was consistent with pancreatic adenocarcinoma. In 
nine (53%) patients the malignant lesions were peritoneal, in seven (41%) patients 
hepatogenic, and in one (6%) patient both peritoneal and hepatic. A flowchart of 
staging laparoscopy findings is shown in figure 1. Of the 74 patients that did not 
show occult metastasis during staging laparoscopy, seven (8%) patients showed 
a new intra-abdominal metastatic lesion on CT-scan within two months from the 
staging laparoscopy. All these new lesions were found in the liver, with five lesions 
being superficial and two lesions found deeper in liver parenchyma.
 In univariate logistic regression of preoperative parameters, serum CEA (µg/L) was 
the only statistically significant risk factor (OR 1.06, 95% CI 1.01-1.11, p=0.02) for occult 
metastasis found at staging laparoscopy. Whereas, gender, age, smoking, tumor size 
and CA 19-9 (kU/L) were not statistically significant predictors. In a multivariate logistic 
regression CEA (µg/L) was the only independent predictor (OR 1.07, 95% CI 1.01 – 
1.14, p=0.03). A CEA (µg/L) ≥ 5 gave a 91% risk for occult metastatic disease during 
staging laparoscopy, while CEA <5 gave a 4% risk for occult metastasis (p=0.04).The 
serum CA19-9 (kU/L) ≥ 35 gave a 79% risk for occult metastasis, while CA19-9 <35 
gave a 19% risk for occult metastasis (p=1.00). All preoperative parameters are shown 
in table 3 and 4. 
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Figure 2. Flowchart of the treatment modalities given to the patients. 
Patients with LAPC 
(N=91)
N=36 (40%)
Biopsy
N=55 (60%)  No suspicious lesion 
N=19 (21%) M-
N=17  (19%)
M+
N=9 (10%)
Peritoneum
N=1 (1%)
Liver + peritoneum
N=7 (8%)
Liver
Patients with LAPC 
(N=91)
FOLFIRINOX treatment 
(N=69)
Radiotherapy treatment 
(N=44)
Best supportive care (N=19)  
No radiotherapy (N=25) 
Surgery (N=6)Follow-up (N=38)
Gemcitabine treatment 
(N=3)
Figure 1 Flowchart of the staging laparoscopy findings.
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Table 2. Baseline characteristics.
Baseline characteristics N=91 (% or IQR)
Age, median [IQR] 64 [56-69]
Gender
Male
Female
37 (41)
54 (59)
WHO PS
0
1
2
14 (15)
74 (81)
3 (3)
Jaundice 44 (48)
Weight loss* 74 (81)
Diabetes 24 (26)
Abdominal pain 71 (78)
BMI, median 24 [21-27]
Smoking
Yes 
Never
Former
Missing
27 (30)
34 (37)
27 (30)
3 (3)
Tumor origin
Head
Distal
56 (62)
35 (38)
Median CA 19.9 (µg/L) 253 [50-1003]
Median CEA (kU/L) 5 [3-11]
Maximum tumor size (mm), median 37 [30-46]
Time between CT-scan and staging laparoscopy (days), 
median
21 days [12 – 32]
*Subjectively assessed by patient
IRQ: Interquartile range
WHO PS: World Health Organization Performance Status 
CA 19.9: Cancer antigen 19.9
CEA: Carcino-embryonaal antigen
 FOLFIRINOX was given to 69 (76%) patients, while 19 (21%) patients received best 
supportive care and three (3%) patients underwent gemcitabine chemotherapy. The 
reasons for patients to receive best supportive care after staging laparoscopy was 
due deterioration of condition (n=9), and patients preference (n=10). The median 
number cycles of FOLFIRINOX was 8 [IQR 4 – 8], with 55% of patients completing 
the scheduled 8 cycles of FOLFIRINOX. There were 35 (51%) adverse events of grade 
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3 or 4 during the FOLFIRINOX treatment. Of the patients that received FOLFIRINOX 
eventually 13 (14%) received conventional radiotherapy, another 31 (34%) patients 
underwent SBRT. Eventually, six (14%) patients underwent a radical resection after 
the FOLFIRINOX and radiotherapy treatment (figure 2). 
 The 1-year OS of all 91 patients was 51% (95% CI 40-61) with a median follow-
up time of 32 months (95% CI 22 - 46), as shown in figure 3. The 1-year survival for 
patients without occult metastasis found on staging laparoscopy was 53% (95% CI 
41% - 64%), while patients with occult metastasis found with occult metastasis on 
staging laparoscopy was 29% (95% CI 47% - 87%) (p=0.11), as shown in figure 4. 
The 1-year OS for patients that completed both FOLFIRINOX and radiotherapy was 
84%(95% CI 69 - 92). 
Table 3. Univariate and multivariate logistic regression for predictive preoperative 
parameters.
Univariate, 
p-value
OR (95% CI) Multivariate,
p-value
OR (95% CI)
Age 0.35 1.03 (0.97 – 1.11) 0.83 0.99 (0.84 - 1.18)
Gender (male) 0.55 0.73 (0.25 – 2.09) 0.72 0.78 (0.04 - 14.88)
Smoking 0.96 1.03 (0.03 – 3.33) 0.34 2.38 (0.22 – 25.98)
Tumor size 0.75 1.01 (0.96 – 1.05) 0.65 0.98 (0.87 – 1.09)
CA 19.9 (µg/L) 0.06 1.00 (1.00 – 1.00) 0.37 1.00 (0.998 - 1.001)
CEA (kU/L) 0.02 1.06 (1.01 – 1.10) 0.03 1.07 (1.01 – 1.14)
Table 4. The number of patients with occult metastasis found with staging laparoscopy and 
CEA value higher than 5.
CEA≥5
No Yes Total
Occult metastasis
No 25 32 57
Yes 1 10 11
Total 26 42 68*
*Preoperative CEA values of 23 patients were unknown before staging laparoscopy. 
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Figure 3. Overall survival of the included patients in this cohort.
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Figure 4. Overall survival of patients with and without occult metastasis found at staging 
laparoscopy.
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Discussion
The yield of staging laparoscopy in 91 patients with LAPC was 19%. LAPC patients 
with occult metastasis had peritoneal and/or liver metastases that were too small 
for detection by state of the art tri-phasic CT of the chest and abdomen. Our study 
includes the largest cohort of patients with LAPC that underwent staging laparoscopy.
Two studies (representing 74 and 68 LAPC patients) and published almost a decade 
ago also evaluated the yield of staging laparoscopy in LAPC patients.[8, 9] They 
found a yield of 34% (95% CI: 24% – 45%) and 35% (95% CI: 25% – 47%) for occult 
metastatic disease detected at staging laparoscopy.[8, 9] A Cochrane meta-analysis 
of seven studies (representing 1015 patients) for staging laparoscopy in (borderline) 
resectable pancreatic cancer showed a yield of 22%[12] The higher yield of about 
1 in 3 LAPC patients found in the previous studies versus 19% in the present study 
could be explained by improvement in the quality of CT scans.[8, 9] Furthermore, 
a specialized radiologist reviewing the CT-scans could also improve the detection 
of occult metastasis found on CT-scan. In addition, multidisciplinary approach of 
LAPC in recent years have resulted in more multidisciplinary board review of these 
patients. This could influence the yield of CT-scan for occult metastatic disease in 
LAPC setting. [13] In our study, all CT-scans were reviewed by a specialized radiologist, 
and all patients were reviewed by a multidisciplinary team. This also could have led to 
a lower yield for staging laparoscopy for LAPC compared to earlier studies. 
 Systemic chemotherapy with FOLFIRINOX has become the standard initial 
treatment for LAPC patients with a good performance status. While no randomized 
controlled trial (RCT) has been published, a patient-level meta-analysis of FOLFIRINOX 
for LAPC found a median OS of 24 months.[14] In this meta-analysis, 64% received 
additional radiotherapy, and 62% eventually underwent a curative-intent resection. 
A systematic review found no RCT to evaluate the benefit of ablative treatments, 
such as radiofrequency ablation (RFA) and irreversible electroporation (IRE), for LAPC 
patients.[15] A more recent RCT randomized 269 LAPC patients with progression-free 
disease after 4 months of systemic treatment to continuation of systemic treatment 
or chemoradiotherapy. No difference in OS could be demonstrated with a hazard ratio 
of 1.03 [95% CI: 0.79-1.34; p=0.83].[16] All ablative treatments have a small but real 
risk of mortality.[14, 15, 17] While an OS benefit of ablative treatment has not been 
definitively shown for LAPC patients, it is even less likely that LAPC patients with occult 
metastatic disease benefit from ablative treatments. Staging laparoscopy in patients 
with LAPC could improve patient selection in clinical trials. A risk of occult metastatic 
disease of about 20% in LAPC patients seems to justify a staging laparoscopy prior 
to consideration of ablative treatments. In the Netherlands, several local ablative 
therapies are studied as subsequent treatment after systemic chemotherapy for LAPC 
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patients. Currently, three ongoing clinical trials examine the safety and potential 
survival benefit of SBRT (ClinicalTrials.gov Identifier: NCT02292745), IRE (ClinicalTrials.
gov Identifier: NCT02791503), and RFA ClinicalTrials.gov Identifier: NCT03690323).
 Radiological imaging is advancing fast with more modalities that aim to detect 
occult metastasis not visible on tri-phasic CT. MRI, 18FDG-PET/CT scan, and contrast-
enhanced ultrasonography all have their benefits and pitfalls for detecting occult 
metastasis in pancreatic cancer. However, superior diagnostic accuracy over CT-scan 
has not been definitively shown for any of these modalities.[18] Furthermore, if these 
new modalities raise the suspicion of metastatic disease, a biopsy with pathological 
confirmation is still required. A biopsy of subcentimeter lesions in the liver or lung can 
be challenging. The advantage of staging laparoscopy over additional imaging is that 
pathological confirmation of occult metastatic disease can be obtained. Circulating 
tumor cells are being examined as a staging parameter in pancreatic cancer.[19-21] 
However, the results are still not definitive for clinical use. 
 Serum CEA was the only independent predictive factor for occult metastasis 
found with staging laparoscopy. Patients with a CEA above 5 µg/L had a risk of 
occult metastasis of 91%. Although these patients have a particularly high risk of the 
presence of occult metastases, this risk is still 4% in patients with a CEA below 5. We 
believe that a staging laparoscopy is justified even in LAPC patients with a somewhat 
lower risk of occult metastases, as a low CEA level does not exclude the presence 
of occult metastasis.[22, 23] Despite higher CEA levels have been associated with 
metastatic disease in pancreatic cancer, no definite conclusions on which CEA cutoff 
level should be used.[24] 
 The 1-year OS in patients without occult metastases was 51% . This was similar to a 
recent patient-level meta-analysis, in which 1-year OS ranged from 33 to 96% across 
studies.[14] The 1-year OS for patients that completed FOLFIRINOX and radiotherapy 
was 84%. Although FOLFIRINOX is currently the most effective treatment for patients 
with LAPC, better treatments are clearly needed.
 The main limitation of our study is that some data (e.g., tumor markers) were 
collected retrospectively, and therefore sometimes missing. Secondly, we used the 
Dutch Pancreatic Cancer Group definition for LAPC; some of the included patients 
would have been classified as borderline resectable when using the NCCN and 
AHPBA/SSO/SSAT classifications.[10, 25, 26] This could have led to an underestimation 
of the yield of staging laparoscopy in LAPC patients. Furthermore, the management 
for borderline resectable pancreatic cancer in the Netherlands is upfront surgery or 
in a trial setting neoadjuvant chemoradiotherapy followed by surgery. Therefore, 
the definitions are of influence on the treatment strategy.[10] In addition, we 
included only patients with a good performance who were eligible for FOLFIRINOX 
and subsequent radiotherapy. We performed staging laparoscopy prior to systemic 
Chapter 3
46
treatment, since we offer all patients without progressive disease SBRT in order to 
improve the R0 resection rate. Although only 14% of patients in our study underwent 
a resection, the resection margins were negative in all patients. The drawback of this 
approach is that initial treatment with systemic chemotherapy remains the same 
whether or not occult metastases are found. However, about 35% of patients respond 
to FOLFIRINOX with the risk that small peritoneal and liver lesions disappear and are 
not found at staging laparoscopy after FOLFIRINOX. These patients would not benefit 
from SBRT, as in the treatment of metastatic disease there are no studies supporting 
radiotherapy for metastatic pancreatic cancer.[27] 
 In conclusion, staging laparoscopy upstages 19% of patients with LAPC to 
metastatic disease. Patients with (occult) metastatic disease are less likely to benefit 
from local therapy. Therefore, staging laparoscopy should be included in the 
pretreatment work-up for patients with LAPC if local therapy is considered. 
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Summary
Background
Thirty-five percent of pancreatic cancer patients have unresectable locally advanced 
pancreatic cancer (LAPC) at diagnosis. Several studies have evaluated systemic 
chemotherapy with FOLFIRINOX for patients with LAPC. We report a patient-level 
meta-analysis of LAPC patients treated with FOLFIRINOX as first-line treatment.
Methods
A systematic literature search was performed in Embase, Medline (ovidSP), Web 
of Science, Scopus, PubMed Publisher, Cochrane, and Google Scholar. Studies 
evaluating FOLFIRINOX as first-line treatment for LAPC were included. The primary 
outcome was overall survival (OS) and secondary outcomes included progression 
free survival (PFS), and grade 3 or 4 adverse events. We collected patient-level data 
from all studies that reported survival outcomes. The Kaplan-Meier method was 
used for survival outcomes. Grade 3 or 4 adverse event rates and the percentage 
of subsequent (chemo)radiation or resection in eligible studies were pooled in a 
random effects model.
Findings
Thirteen eligible studies representing 689 patients were included of whom 355 had 
LAPC. Eleven studies, representing 315 LAPC patients, reported survival outcomes 
and were eligible for patient-level meta-analysis. The median OS ranged from 10·0 to 
32·7 months across studies with a patient-level median OS of 24·2 months [95% CI: 
21·6 - 26·8 months]. The median PFS ranged from 3·0 to 20·4 months across studies 
with a patient-level median PFS of 15·0 months [95% CI: 13·8 - 16·2 months]. In 10 
studies representing 490 patients, 296 Grade 3 or 4 adverse events were reported 
(i.e. 60·4 events per 100 patients). No death was attributed to FOLFIRINOX toxicity. 
Subsequent treatments included (chemo)radiation (63·5%) and surgical resection 
(25·9%).
Interpretation
Patients with LAPC treated with FOLFIRINOX had a median OS of 24·2 months that 
is far superior to previously reported OS with gemcitabine. Future research should 
evaluate these promising results in a randomized controlled trial and determine 
which patients might benefit from (chemo)radiation or a resection after FOLFIRINOX.
Funding
No funding has been received for this work. 
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Research in context
Evidence before this study
Pancreatic cancer is the fourth most common cause of cancer death. Thirty-five 
percent of all pancreatic cancer patients present with locally advanced pancreatic 
cancer (LAPC). Palliative gemcitabine has been the standard of care for LAPC patients 
for over a decade with a modest survival benefit of about 3 months compared to 
best supportive care. In patients with metastatic pancreatic cancer, FOLFIRINOX 
was shown to improve the median overall survival (OS) to 11 months compared to 7 
months with gemcitabine. Recently, several studies have evaluated FOLFIRINOX for 
LAPC patients. 
Added value of this study
This is the first meta-analysis combining patient-level data of 11 studies with 315 
LAPC patients treated with FOLFIRINOX. We found a pooled median OS of 24 months 
in LAPC patients after treatment with FOLFIRINOX. 
 Implications of all the available evidence
We found a median OS of 24 months in LAPC patients treated with FOLFIRINOX 
appears that is far superior to the previously reported OS with gemcitabine of 6 to 
13 months. However, confirmation of these results in a randomized controlled trial 
is needed. Meanwhile, the observed favorable survival after FOLFIRINOX should be 
discussed with LAPC patients with a good performance status (ECOG 0-1).
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Introduction
Pancreatic cancer is the fourth leading cause of cancer-related death with only a 
6% survival at 5 years.[1, 2] At the time of diagnosis, about 15% of patients have 
resectable disease (stage I or II), 35% locally advanced pancreatic cancer (LAPC, 
stage III), and 50% metastatic disease (stage IV).[3] The diagnosis of resectable 
disease and LAPC is determined by the extent of tumor contact with the superior 
mesenteric artery, celiac artery, superior mesenteric vein, and portal vein. The risk of 
a positive resection margin increases with increasing tumor contact of the arteries 
and/or veins. LAPC is considered unresectable because patients who underwent a 
resection with positive margin had the same overall survival (OS) as patients who 
did not undergo a resection.[4] Several definitions for LAPC have been proposed 
that vary mainly in the extent of tumor contact. The two commonly used criteria 
are from the National Comprehensive Cancer Network (NCCN, USA) and from the 
joint consensus conference of the Americas Hepato-Pancreato-Biliary Association 
(AHPBA), the Society of Surgical Oncology (SSO), and the Society for Surgery of the 
Alimentary Tract (SSAT).[5, 6] The NCCN and AHPBA/SSO/SSAT definitions for LAPC 
are summarized in table 1. 
Table 1. NCCN and AHPBA/SSO/SSAT definitions for LAPC.
NCCN AHPBA/SSO/SSAT
No distant metastasis No distant metastasis
Solid tumor contact with SMA and/or CA >180 degrees Circumferential encasement of SMA and/or CHA
Solid tumor contact with the first jejunal SMA branch and/or 
aortic involvement. 
Abutment of CA due to tumor involvement
Unreconstructable SMV and/or PV due to tumor involvement 
or occlusion
Unreconstructable SMV and/or PV due to tumor involvement or 
occlusion
Contact with most proximal draining jejunal branch into SMV.
SMA: Superior Mesenteric Artery
CA: Coeliac Axis
CHA: Common Hepatic Artery
SMV: Superior Mesenteric Vein
PV: Portal Vein
 Systemic chemotherapy is the main treatment for patients with LAPC or metastatic 
disease. For decades 5-fluorouracil (5-FU) was the standard palliative treatment for 
pancreatic cancer. In 1997, a randomized controlled trial (RCT) including metastatic 
and LAPC patients showed an improved survival of 5·6 months for patients treated 
with gemcitabine versus 4·4 months with 5-FU (p=0·0025).[7] In 2011, an RCT (the 
PRODIGE 4/ACCORD 11 RCT) found a median OS of 11·1 months with FOLFIRINOX 
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versus 6·8 months with gemcitabine (p<0·0001) in patients with metastatic disease.
[8] No RCT has been performed with FOLFIRINOX for LAPC patients. Many case series 
with FOLFIRINOX for LAPC patients have been published in the past four years, but 
the sample size of most studies was too small to draw definitive conclusions about 
efficacy and safety of FOLFIRINOX in LAPC patients. The aim of this paper was to 
perform a systematic review and patient-level meta-analysis to evaluate FOLFIRINOX 
as first-line treatment for patients diagnosed with LAPC.
Methods
This review followed the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) guidelines and the Cochrane Handbook for Systematic Reviews of 
Interventions.[9, 10] It was registered at the University of York PROSPERO 2015 with 
registration number CRD42015017354.[11]
Selection criteria and search strategy
Eligible studies included treatment naïve patients of any age who received 
FOLFIRINOX as first-line treatment for LAPC, regardless of subsequent other treatment. 
The regular FOLFIRINOX regimen as described in the PRODIGE 4 trial consisted of 2-h 
intravenous infusion of oxaliplatin (85 mg/m2) followed by a 2-h intravenous infusion 
of leucovorin (400 mg/m2) concomitantly with a 90-min intravenous infusion of 
irinotecan (180 mg/m2), followed by a bolus (400 mg/m2) and a 46-h continuous 
infusion (2,400 mg/m2) of 5-FU. The duration of a cycle is 2 weeks.[12]
 A systematic literature search was performed in Embase, Medline (ovidSP), Web 
of Science, Scopus, PubMed Publisher, Cochrane, and Google Scholar. The last search 
was run on July 2nd, 2015. Search terms included: FOLFIRINOX, folinic acid, fluorouracil, 
irinotecan, oxaliplatin, pancreas cancer, and relevant variants thereof. No language or 
publication date restrictions were imposed. The grey literature was not accessed (i.e. 
literature that has not been formally published).[13] See the appendix A, for the detailed 
search strategy.
 After removing duplicates, abstracts were independently reviewed by two authors 
(MS and BRB). Differences between authors were resolved by discussion. Abstracts were 
excluded if the record type was a case report, review, letter to the editor, or a conference 
abstract without full text. When eligibility criteria appeared to be met, the full text was 
retrieved for further evaluation. Full text studies were excluded if the study used a regimen 
other than FOLFIRINOX, used FOLFIRINOX in combination with other chemotherapy at 
the same time, investigated FOLFIRINOX not as first-line treatment, did not include LAPC 
patients, was a review, or if the same patient cohort was presented in another study. 
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Outcome
The primary outcome measure was OS. Secondary outcomes were progression 
free survival (PFS), grade 3 or 4 adverse events, percentage of (chemo)radiation, 
percentage of resection after FOLFIRINOX, and percentage of R0 resection.
 Two authors (MS and BRB) independently extracted information from the full texts 
using a predefined data extraction sheet. Disagreements were resolved by discussion.
The following study details were extracted: study characteristics (first author, year 
of publication, study design), study population (total number of patients analyzed, 
patient groups, tumor stage, location, and local extend of the disease), diagnostic 
work-up (staging laparoscopy), type of intervention (FOLFIRINOX regimen and 
number of administered cycles, percentage of (chemo)radiation, resection, and R0 
resection), and outcome (duration of follow-up, OS, PFS, grade 3 or 4 adverse events). 
Updated patient-level data on OS and PFS were obtained from the authors of all 
studies presenting survival outcomes. Percentage of (chemo)radiation and resection 
were obtained from the studies and are not patient-level data.
Patient-level data collection
Patient-level data on OS and PFS were obtained from the authors of all studies 
presenting survival outcomes. The authors of the original studies updated and 
checked their patient-level data. No patient-level data was missing on survival 
outcomes. Results other than survival outcomes (e.g., toxicity data or percentage of 
(chemo)radiation and resection) are not based on patient-level data.
 Statistical analysis To ascertain the risk of bias, each study was assessed (MS) using 
the scoring system developed by the Critical Appraisal Skill Program (CASP). The CASP 
tool is a critical appraisal tool for observational studies to assess the methodological 
quality of the individual studies.(14) Publication bias was assessed with a funnel plot.
[15]
 Survival outcomes (OS and PFS) were evaluated with the Kaplan-Meier method 
using patient-level data in SPSS version 21.[16] Studies presenting only LAPC patients 
who underwent a resection after FOLFIRINOX were excluded from survival analysis to 
avoid selection bias. A post hoc subgroup analysis of the (patient-level) median OS of 
studies with at least 20 LAPC patients was conducted. 
 Grade 3 or 4 adverse events were calculated as number of events per 100 patients 
and pooled in random effects models using the statistical MedCalc package (version 
16·2).[17] Pooled percentages of (chemo)radiation, resection, and R0 were calculated 
in random effects models using the statistical MedCalc package (version 16·2).
[17] Random (instead of fixed) effects models were used because of anticipated 
heterogeneity in LAPC definitions across studies.[18] We tested for heterogeneity 
with visual inspection of the forest plots and used I2 as measure of consistency across 
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studies. A Spearman’s correlation was calculated (as post hoc analyses) across studies 
between (chemo)radiation and OS, resection and OS, and the median number of 
administered FOLFIRINOX cycles and OS. 
 No funding has been received for this work. The corresponding author had full 
access to all of the data and the final responsibility to submit for publication.
Results
Studies
The search criteria resulted in 840 potentially eligible studies. After screening of 
the abstracts, 30 studies were selected for full text assessment, of which 13 studies 
fulfilled the inclusion criteria.[12, 19-30] The excluded studies are presented in the 
appendix B. Figure 1 presents the flowchart.
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Outcomes
The primary outcome measure was overall survival. 
Secondary outcomes were progression-free survival; 
grade 3 or 4 adverse events; and the proportion of patients 
who underwent radiotherapy or chemoradiotherapy, 
surgical resection after FOLFIRINOX, and R0 resection.
Data extraction
MS and BRB independently extracted information from 
the full texts using a predeﬁ ned data extraction sheet, 
with disagreements resolved by discussion. Extracted 
study details were study characteristics (ﬁ rst author, 
year of publication, study design), study population 
(total number of patients analysed, patient groups, 
tumour stage, location, and local extent of the disease), 
diagnostic work-up (staging laparoscopy), type of 
intervention (FOLFIRINOX regimen and number of 
administered cycles, and the proportion of patients 
who underwent radiotherapy or chemoradiotherapy, 
resection, and R0 resection), and outcome (duration of 
follow-up, overall survival, progression-free survival, 
grade 3 or 4 adverse events).
We obtained updated patient-level data for overall and 
progression-free survival from the investigators of all 
studies presenting survival outcomes, who checked their 
data. No patient-level data were missing for survival 
outcomes. Results other than survival outcomes—
ie, toxicity data or proportion of radio therapy and chemo-
radiotherapy and resection—were obtained from the 
studies and are not patient-level data.
Statistical analysis
To ascertain the risk of bias, MS assessed each study with 
the scoring system developed by the Critical Appraisal 
Skill Program (CASP).14 The CASP is a critical appraisal 
tool for observational studies to assess the methodological 
quality of the individual studies. Publication bias was 
assessed with a funnel plot.15
We evaluated survival outcomes with the Kaplan–Meier 
method with use of patient-level data in SPSS (version 21). 
Studies presenting only patients with locally advanced 
pancreatic cancer who underwent resection after 
FOLFIRINOX were excluded from survival analysis to 
avoid selection bias. We did a post-hoc subgroup analysis 
of the patient-level median overall survival of studies 
with at least 20 patients with locally advanced disease.
Grade 3 or 4 adverse events were calculated as number of 
events per 100 patients and pooled in random-eﬀ ects 
models with MedCalc (version 16.2). Pooled proportions of 
radiotherapy and chemoradiotherapy, resection, and R0 
were calculated in random-eﬀ ects models with MedCalc 
(version 16.2). We used random-eﬀ ects rather than 
ﬁ xed-eﬀ ects models because of anticipated heterogeneity 
in deﬁ nitions of locally advanced pancreatic cancer across 
studies.16 We tested for heterogeneity with visual inspection 
of the forest plots, and used the I² statistic to measure 
the consistency of eﬀ ects across studies. A Spearman’s 
correlation coeﬃ  cient was calculated post-hoc across 
studies between radiotherapy and chemoradiotherapy and 
overall survival, resection and overall survival, and the 
median number of administered FOLFIRINOX cycles and 
overall survival. This study is registered with PROSPERO, 
number CRD42015017354.17
Role of the funding source
There was no funding source for this study. The 
corresponding author had full access to all the data and 
the ﬁ nal responsibility to submit for publication.
Results
Figure 1 shows the ﬂ ow diagram for study selection. 
We identiﬁ ed 840 potentially relevant studies. After 
screening of the abstracts, 30 studies were selected for 
full-text assessment, of which 13 studies fulﬁ lled the 
inclusion criteria.12,18–29 The appendix (pp 2, 3) presents 
details of the excluded studies.
One study was a prospective non-randomised phase 2 
study,12 one was a prospective cohort study,25 and 11 studies 
were retrospective cohort studies.18–24,26–29 Three studies 
used the NCCN criteria to deﬁ ne locally advanced 
pancreatic cancer21,28,29 and three studies used the 
AHPBA/SSO/SSAT criteria.22,23,27 The other seven studies 
determined locally advanced disease on the basis 
of multidisciplinary review board or retro spective 
assessment of pretreatment imaging.12,18–20,24–26 Only 
three studies presented a patient cohort including only 
patients with locally advanced pancreatic cancer.21,25,29 
None of the studies described a staging laparoscopy as 
Figure 1: Flow chart of study selection
FOLFIRINOX=leucovorin and ﬂ uorouracil plus irinotecan and oxaliplatin. 
LAPC=locally advanced pancreatic cancer.
30 studies retrieved for detailed assessment
13 studies included in meta-analysis
(689 patients)
11 studies included in patient-level
meta-analysis (315 patients with LAPC;
survival outcomes only)
840 studies identified
810 excluded based on abstract
17 excluded
3 used a regimen other than FOLFIRINOX
4 investigated FOLFIRINOX combined with
other chemotherapy
3 investigated FOLFIRINOX not first-line therapy
5 had no LAPC patients
1 was a review study
1 included a patient cohort presented previously
Figure 1. Flowchart of the included studies. 
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Study characteristics
One study was a prospective non-randomized phase II study,[12] one was a 
prospective cohort study,[26] and the other eleven studies were retrospective cohort 
studies.[19-25, 27-30] Three studies used the NCCN criteria[22, 29, 30], and three 
studies used the AHPBA/SSO/SSAT criteria[23, 24, 28] to define LAPC. The other seven 
studies determined LAPC based on multidisciplinary review board or retrospective 
evaluation of pretreatment imaging.[12, 19-21, 25-27] Only three studies presented a 
patient cohort including only LAPC patients.[22, 26, 30] None of the studies described 
a staging laparoscopy as part of the diagnostic work-up. Study characteristics are 
presented in Table 2. The study quality assessments and funnel plot are presented in 
the appendix C.
Patient characteristics
The thirteen studies included a total of 689 patients, of whom 355 patients had LAPC. 
All other patients had (borderline) resectable, metastatic, or recurrent disease. The 
total population consisted of 53% male patients and the median age ranged from 56 
to 66 years (Table 2).
Survival
Eleven studies representing 315 LAPC patients were available for patient-level survival 
analysis. One study with 25 LAPC patients was excluded from survival analyses 
because only patients who underwent a resection after FOLFIRINOX were included.
[28] Another study with 10 LAPC patients did not report survival outcomes.[23] 
One study included 5 patients who received FOLFIRINOX not as first-line treatment 
and these patients were excluded from the survival analysis.[27] All studies defined 
survival as the time from the start of FOLFIRINOX. The median OS ranged from 10·0 
to 32·7 months across studies with a patient-level median OS of 24·2 months [95% CI 
21·6 - 26·8 months]. OS at 1 year was 80·0% [95% CI: 74·7 - 84·4] and at 2 years 50·2% 
[95% CI: 42·9 - 57·5]. A post hoc analysis including only the five studies with at least 
20 LAPC patients found a median OS ranging from 21·1 to 26·0 months.[20, 22, 26, 
29, 30] The median PFS ranged from 3·0 to 20·4 months across studies with a patient-
level median PFS of 15·0 months [95% CI: 13·8 - 16·2 months]. Figure 2 presents the 
survival curves of all individual studies as well as the pooled survival curves for OS 
and PFS. 
 Two studies used a dose modification of the FOLFIRINOX dose described in the 
PRODIGE-4 trial.[12] Median OS was 21.2 months in the study that did not give a bolus 
of 5-FU [20] and median OS was 26.0 months in the study with 80% dose intensity.[30] 
The median number of administered cycles was reported in nine of eleven studies 
and ranged from 3 to 11 cycles, where each cycle was 2 weeks.[12, 20-22, 24-27, 30] 
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Figure 2. Kaplan-Meier survival curves for PFS and OS. Numbers at risk at x-axis are the 
number of patients at risk for the pooled data. 
0 12 24 36
0.0
0.2
0.4
0.6
0.8
1.0
Pooled data
Conroy
Marthey
Mahaseth
Moorcraft
Sadot
Mellon
Faris
Gunturu
Hohla
Peddi
Hosein
144 109 84 63 44 33 25 13 1118311 288 230 186Numbers
at risk
315
OS (months)
Po
rp
or
tio
n
0 12 24 36
0.0
0.2
0.4
0.6
0.8
1.0
Pooled data
Conroy
Marthey
Mahaseth
Moorcraft
Sadot
Mellon
Faris
Gunturu
Hohla
Peddi
Hosein
99 62 42 25 18 15 10281 249 187 135Numbers
at risk
315
PFS (months)
Po
rp
or
tio
n
463
No significant correlation was found across studies between the median number of 
cycles and median OS (p=0·95) (appendix D).
Toxicity data
In eight studies, the adverse events were reported using the Common Terminology 
Criteria for Adverse Events (CTCAE). Two studies did not state which criteria were used.
[19, 22] Three studies did not report toxicity data.[19, 28, 29] A total of 490 patients 
in 10 studies were analyzed for grade 3 or 4 adverse events. Of these ten studies, 
eight studies used the full dose of FOLFIRINOX as described in the PRODIGE-4 trial.
[12] Two studies had a modification of this dose with one study not giving a bolus 
of 5-FU (20) and another study with 80% dose intensity.[30] No deaths attributed to 
FOLFIRINOX were reported. In 10 studies representing 490 patients, 296 Grade 3 or 
4 adverse events were reported (i.e. 60·4 events per 100 patients). All grade 3 or 4 
adverse events are presented in table 4. The pooled event rates per 100 patients for 
grade 3 or 4 adverse events are presented in forest plots (Figure 4). The pooled rates 
per 100 patients were 19·6 (95% CI: 10·9–29·9, I2 = 83%) for neutropenia, 5·9 (95% 
CI: 2·9-9·8, I2 = 53%) for thrombocytopenia, 8·2 (95% CI: 5·0 –12·1, I2 = 36%) for 
diarrhea, 8·8 (95% CI: 5·0 – 13·5, I2 =36%) for vomiting, and 11·7 (95% CI: 7·3 – 17·0, 
I2 = 51%) for fatigue. 
Table 3. Median PFS and OS for patients with LAPC.
Author N patients Median follow-up, 
months (IQR)
Median PFS,
months
Median OS,
months
Conroy (12) 11 26,6 (26,0-33,4) 7,6 15,7
Faris (22) 22 54,0 (32,7-55,3) 11,8 24,7
Gunturu (25) 16 33,1 (11,4-49,3) 17,3 25,3
Hohla (19) 6 Not applicable 3,0 10,0
Hosein (24) 14 36,1 (32,9-38,8) 17,3 32,7
Mahaseth (20) 20 4,0 (4,0-4,0) 11,0 21,2
Marthey (26) 77 11,3 (7,8-17,6) 18,5 21,1
Mellon (29) 21 10,5 (7,3-20,1) 20,4 24,0
Moorcraft (27) 8 15,9 (15,4-16,3) 12,8 18,4
Peddi (21) 19 11,4 (8,2-16,2) 12,4 Not reached
Sadot (30) 101 12,0 (8,0-18,0) 16,0 26,0
Pooled patient-level data 315 12,3 (8,0-20,5) 15,0 24,2
Median follow-up of patients alive at last follow-up.
IQR: Interquartile range
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 The use of granulocyte-colony stimulating factor (G-CSF) was reported in eight 
studies representing 368 patients.[12, 20-22, 24-27] Of those 368 patients, 269 
(73·1%) received G-CSF. Four studies gave G-CSF as primary prophylaxis.[20, 22, 25, 
26] one study as secondary prophylaxis(12), and three studies left it to the discretion 
of the treating physician. [21, 24, 27] 
Figure 3. Forest plots of reported grade 3 or 4 adverse event rates.
Totals (i.e. pooled rates) are expressed as the number of events per 100 patients. Totals were calculated using 
random effects modeling and differ slightly from table 4. 
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reported in 31% of patients in the FOLFIRINOX group 
versus 66% patients in the gemcitabine group (p<0·001). 
Future studies should focus on predictive factors for 
the eﬃ  cacy of FOLFIRINOX to minimise toxicity in 
non-responsive patients.
We found that almost two-thirds of patients received 
radiotherapy or chemoradiotherapy after FOLFIRINOX. 
There was no signiﬁ cant correlation between use 
of radiothera y or chemoradiotherapy and overall 
survivals across studies. However, this analysis was not 
done at the patient level. The rationale for use of 
radiotherapy and chemoradiotherapy is that about 30% 
of patients with pancreatic cancer die from local 
progression in the absen e of metastatic disease.34 
Patients with locally advanced disease who do not 
develop metastatic disease during systemic treatment 
might beneﬁ t from local control of the tumour with 
radiotherapy or chemotherapy. The role of these 
therapies in locally advanced disease is still unclear 
because of conﬂ icting results.35 In a phase 3 trial 
(LAP 07),36 442 patients were randomly assigned to 
receive 4 months of gemcitabine with or without 
erlotinib. Patients with controlled disease after 4 months 
were then randomly assigned to receive either continued 
systemic chemotherapy or chemoradiotherapy. Median 
survival was 16·4 months (95% CI 15·5–18·5) for 
patients continuing chemo therapy and 15·3 months 
(13·9–17·3) for those proceeding to chemoradiotherapy 
Figure 3: Forest plots showing rates of grade 3 or 4 adverse events
Totals (ie, pooled rates) were calculated with random-eﬀ ects models and diﬀ er slightly from those shown in Table 4.
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Figure 4. Forest plots of the percentage of (chemo)radiation, resection, and R0 resection.
Totals (i.e. pooled percentages) were calculated using random effects modeling and differ slightly from table 
3 were totals were calculated as overall proportions.
Table 5. Percentages of (chemo)radiation and resection and R0 resection for LAPC patients.
Author N patients analyzed (Chemo)radiation (%) N Resected (%) N R0 resected (%)
Boone (23) 10 5 (50,0%) 2 (20,0%) 1 (50,0%)
Conroy (12) 11 NR 0,0% NA
Faris (22) 22 20 (90,9%) 5 (22,7%) 5 (100,0%)
Gunturu (25) 16 NR 2 (12,5%) NR
Hohla (19) 6 2 (33,3%) 2 (33,3%) NR
Hosein (24) 14 9 (64,3%) 6 (42,9%) 5 (83,3%)
Mahaseth (20) 20 10 (50,5%) 4 (20,0%) 3 (75,0%)
Marthey (26) 77 24 (31,2%) 28 (36,4%) 25 (89,3%)
Mellon (29) 21 21 (100,0%) 5 (23,8%) 5 (100,0%)
Moorcraft (27) 8 NR 2 (25,0%) NR
Peddi (21) 19 NR 4 (21,1%) NR
Sadot (30) 101 63 (62,4%) 31 (30,7%) 16 (51,6%)
Total 325 154 (57%) 91 (28%) 60 (74%)
Totals were calculated as overall proportions and differ slightly from pooled percentages in Figure 3 
that were calculated using random effects modeling.
NA: not applicable, NR: not reported
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(hazard ratio 1·03, 95% CI 0·79–1·34; p=0·83).36 
Two randomised controlled trials are being done to 
assess the beneﬁ t of radiotherapy and chemoradio-
therapy after induction chemotherapy (NCT01827553, 
NCT02024009). Stereotactic body radio therapy has 
shown promising results in tumour control in patients 
with locally advanced pancreatic cancer.37,38 The feasibility 
and eﬃ  cacy of this procedure after induction 
FOLFIRINOX is being investigated in clinical trials 
(NCT01926197, NCT02292745).
In our study, about a quarter of patients underwent 
surgical resection after FOLFIRINOX, of whom 
roughly three-quarters had an R0 resection. Substantial 
heterogeneity across studies in the proportion of patients 
undergoing resection is explained by an absence of 
consensus in the literature on selection of patients for 
resection after FOLFIRINOX.39 There was no signiﬁ cant 
correlation across studies between the proportion of 
patients undergoing resection and overall survival. 
However, this analysis was not done at the patient level. 
Future studies should assess whether resection after 
FOLFIRINOX improves overall survival or quality of life, 
and how to select patients for resection.
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Figure 4: Forest plots showing the percentage of patients who underwent radiotherapy or chemoradiotherapy, resection, and R0 resection 
Totals (ie, pooled percentages) were calculated with random-eﬀ ects models and diﬀ er slightly from those shown in Table 3, which were calculated as 
overall proportions.
Number 
of 
patients
Radiotherapy or 
chemoradiotherapy
Resection R0 
resection
Boone22 10 5 (50%) 2 (20%) 1 (50%)
Conroy12 11 NR 0 NA
Faris21 22 20 (91%) 5 (23%) 5 (100%)
Gunturu24 16 NR 2 (13%) NR
Hohla18 6 2 (33%) 2 (33%) NR
Hosein23 14 9 (64%) 6 (43%) 5 (83%)
Mahaseth19 20 10 (50%) 4 (20%) 3 (75%)
Marthey25 77 24 (31%) 28 (36%) 25 (89%)
Mellon28 21 21 (100%) 5 (24%) 5 (100%)
Moorcraft26 8 NR 2 (25%) NR
Peddi20 19 NR 4 (21%) NR
Sadot29 101 63 (62%) 31 (31%) 16 (52%)
Total 325 154 (57%) 91 (28%) 60 (74%)
Data are n (%), unless otherwise speciﬁ ed. Totals were calculated as overall 
proportions and diﬀ er slightly from pooled percentages in Figure 3 that were 
calculated using random-eﬀ ects modelling. NA=not applicable. 
NR=not reported.
Table 4: Proportion of patients who underwent radiotherapy or 
chemoradiotherapy, resection, and R0 resection 
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Subsequent treatment
Results on subsequent treatments were not based on patient-level data. The 
percentage of (chemo)radiation ranged from 31·2% to 100·0% across studies. (Chemo)
radiation was reported in eight studies representing 271 patients of whom 154 
patients received (chemo)radiation (56·8%) after FOLFIRINOX.(19, 20, 22-24, 26, 29, 
30) The pooled percentage of (chemo)radiation in a random effects model was 63·5% 
(95% CI: 43·3% - 81·6%, I2= 90%). The modalities were stereotactic body radiotherapy 
(SBTR) in three studies[20, 23, 29], chemoradiation in three studies[22, 24, 30], and 
conventional radiation therapy in two studies.[19, 26] No significant association was 
found across studies between the percentage of (chemo)radiation and OS (p=0·12) 
(appendix D).
 The percentage of resection for LAPC ranged from 0·0% to 42·9% across studies. 
The percentage of margin negative (i.e. R0) resection of patients who underwent 
a resection ranged from 50% to 100% (Table 5). Four studies did not report the 
percentage of an R0 resection.[19, 21, 25, 27] One study only presented those 
patients that underwent a resection after FOLFIRINOX and was not included in the 
analysis for the percentage of resection.[28] In twelve studies, 91 of 325 patients 
(28·0%) underwent a resection after FOLFIRINOX for LAPC. The pooled percentage 
of resection in a random effects model was 25·9% (95% CI: 20·2% - 31·9%, I2= 24%). 
Resection margin status was missing in 10 patients. An R0 resection was reported 
in 60 out of 81 patients (74·1%). The pooled percentage of R0 resection in a random 
effects model was 78·4% (95% CI: 60·2% - 92·2%, I2= 64%) (Figure 4). No significant 
correlation was found across studies between percentage of resection and OS 
(p=0·39) (appendix D).
Discussion
We found thirteen studies that assessed FOLFIRINOX as first-line treatment for LAPC. 
The patient-level meta-analysis of eleven studies representing 315 patients found a 
median PFS of 15·0 months and a median OS of 24·2 months.
 In 2005, Conroy et al. first reported a nonrandomized phase II trial that evaluated 
FOLFIRINOX in patients with LAPC or metastatic pancreatic cancer.[12] In this study, 
11 out of 46 patients (23·9%) had LAPC with a median OS of 15·7 months. In 2011, 
a phase III trial (PRODIGE 4/ACCORD 11 trial) demonstrated the effectiveness of 
FOLFIRINOX in the setting of metastatic pancreatic cancer.[8] Since then many case 
series evaluating FOLFIRINOX for LAPC have been published, with recently the largest 
series of Sadot et al. with 101 patients.[28] All studies with at least 20 patients found 
a similar median OS ranging from 21·1 to 26·0 months.[20, 22, 26, 29, 30] The median 
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OS of 24·2 months after FOLFIRINOX in patients with LAPC compares favorably to 
a median OS of 6 to 13 months that was found for gemcitabine in patients with 
LAPC.[31, 32] However, the present meta-analysis included only non-randomized 
studies and the favorable OS after FOLFIRINOX may be partly attributable to patient 
selection. A phase III trial comparing gemcitabine with FOLFIRINOX in patients with 
LAPC is currently recruiting patients (PRODIGE 29-NEOPAN).[33] 
 The median OS of 24·2 months that we found in patients with LAPC (stage III) 
treated with FOLFIRINOX is the same as the median OS for patients with resected 
pancreatic cancer (stage I or II) followed by adjuvant gemcitabine in the ESPAC-3 
trial.[34] This raises the question whether neoadjuvant FOLFIRINOX could also 
benefit patients with resectable pancreatic cancer. Neoadjuvant chemotherapy with 
FOLFIRINOX is attractive for several reasons: pancreatic cancer is a systemic disease at 
diagnosis in almost all patients,[35] the percentage of an R0 resection is expected to 
be higher with FOLFIRINOX, and a futile resection is avoided in patients who develop 
metastatic disease during chemotherapy. At least four phase II trials are ongoing to 
investigate neoadjuvant FOLFIRINOX in patients with resectable pancreatic cancer.
[36-39]
 No mortality attributed to FOLFIRINOX was reported. The pooled grade 3 or 4 
adverse event rates per 100 patients were 60·4 for all grade 3 or 4 adverse events, 
19·6 for neutropenia, 5·9 for thrombocytopenia, 8·2 for diarrhea, 8·8 for vomiting, and 
11·7 for fatigue. The only prospective study in this meta-analysis found considerably 
higher rates of grade 3 or 4 adverse events, almost certainly due to more accurate 
ascertainment of adverse events in prospective studies.[12] Thus the pooled adverse 
event rates are likely an underestimate of the actual adverse event rate of FOLFIRINOX. 
The PRODIGE-4 trial also showed a better safety profile for gemcitabine compared 
to FOLFIRINOX in patients with metastatic pancreatic cancer.[8] In the same study, 
however, a definitive degradation of quality of life at 6 months was reported in 31% 
in the FOLFIRINOX group versus 66% in the gemcitabine group (p<0·001). Future 
studies should focus on predictive factors for the efficacy of FOLFIRINOX to minimize 
toxicity in nonresponsive patients. 
 We found that 63·5% of patients received (chemo)radiation after FOLFIRINOX. 
Across studies no significant correlation was found between the use of (chemo)
radiation and OS. However, this analysis was not performed at the patient-level. The 
rationale of (chemo)radiation is that about 30% of pancreatic cancer patients die from 
local progression in the absence of metastatic disease.[40] LAPC patients who do 
not develop metastatic disease during systemic treatment might benefit from local 
control of the tumor with (chemo)radiation. The role of (chemo)radiation in LAPC is 
still unclear due to conflicting results.[41] In a phase III trial (LAP 07), 442 patients were 
randomized to receive 4 months of gemcitabine with or without erlotinib. Patients 
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with controlled disease after 4 months were then randomized to either continued 
systemic chemotherapy or chemoradiation. The median survival was 16·4 months for 
continuing chemotherapy and 15·3 months for proceeding to chemoradiation (HR: 
1·03; 95% CI: 0·79-1·34; p=0·83).[42] Two ongoing RCTs are evaluating the benefit of 
(chemo)radiation after induction chemotherapy.[43, 44] Stereotactic body radiation 
therapy (SBRT) has shown promising results in tumor control in patients with LAPC.
[45, 46] The feasibility and efficacy of SBRT following induction FOLFIRINOX is being 
evaluated in clinical trials.[47, 48]
 We found that in 25·9% of LAPC patients underwent a resection after FOLFIRINOX, 
of whom 78·4% had an R0 resection. Considerable heterogeneity across studies in 
the percentage of resection is explained by lack of consensus in the literature on 
selecting patients for resection after FOLFIRINOX.[49] No significant correlation 
was found across studies between the percentage of resection and OS. However, 
this analysis was not performed at the patient level. Future studies should evaluate 
whether resection after FOLFIRINOX improves OS or quality of life, and how to select 
patients for resection. 
The main limitation of this patient-level meta-analysis is that all studies were 
nonrandomized and most studies had a retrospective design. Retrospective studies 
are known to underreport toxicity outcomes. Moreover, PFS may be biased due to 
the lack of standardized on-treatment imaging in retrospective studies. Secondly, the 
results of this meta-analysis may be biased because studies used different definitions 
for LAPC; three studies used the NCCN criteria[22, 29, 30], three studies used the 
AHPBA/SSO/SSAT criteria,[23, 24, 28] and the other seven studies diagnosed LAPC 
based on multidisciplinary review board or retrospective evaluation of pretreatment 
imaging.[12, 19-21, 25-27] The NCCN and AHPBA/SSO/SSAT definitions for LAPC 
vary mainly in the extent of vascular involvement (Table 1); definitions for LAPC 
were ambiguous in the other seven studies. Consensus on the definition of LAPC is 
required to improve comparison across future studies. Thirdly, it was not reported 
how eligibility for FOLFIRINOX was determined: did nearly all patients with LAPC 
receive FOLFIRINOX, or only a small subgroup of the fittest patients? Consequently, 
it is unclear which LAPC patients can anticipate a median OS of 24·2 months with 
FOLFIRINOX. Fourthly, after first-line FOLFIRINOX many patients had additional 
cancer-directed treatments including chemotherapy, targeted treatment, (chemo)
radiation, and surgical resection. These additional treatments varied within and 
across studies. Insufficient data was available to evaluate the impact of these 
additional treatments on survival outcomes. However, despite the large variation in 
additional treatments, the median OS was very consistent across the studies with 
at least 20 LAPC patients. Finally, no study reported standard pretreatment staging 
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laparoscopy, as recommended by a consensus statement.[6] Staging laparoscopy 
has been demonstrated to upstage patients to metastatic disease in up to a third of 
patients in two studies.[50, 51] Better staging may yield OS beyond 24 months for 
LAPC patients treated with FOLFIRINOX.
 In conclusion, this patient-level meta-analysis found a median OS of 24·2 months 
after FOLFIRINOX in patients with LAPC. This is superior to the median OS reported 
for gemcitabine in LAPC patients of 6 to 13 months.[31, 32] An ongoing phase III trial 
will provide level I evidence regarding FOLFIRINOX in LAPC patients.[33]
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Appendix A
Table 1. Articles retrieved from different electronic databases.
Electronic database Retrieved Unique studies
Embase.com 741 730
Medline (OvidSP) 163 14
Web-of-science 199 43
Scopus 194 12
PubMed publisher 7 3
Cochrane central 12 0
Google scholar 100 38
Total 1416 840
Last search in electronic databases performed on the 2nd of July 2015.
Detailed search strategy
Embase.com
((‘folinic acid’/exp AND fluorouracil/exp AND irinotecan/exp AND oxaliplatin/exp 
AND ‘drug combination’/exp AND (‘pancreas cancer’/de OR ‘pancreas tumor’/de OR 
‘pancreas adenoma’/de OR ‘pancreas adenocarcinoma’/de OR ‘pancreas carcinoma’/
de OR ‘pancreas islet cell carcinoma’/de OR (pancrea* NEAR/3 (cancer* OR neoplas* OR 
tumo* OR adenocarcinom* OR carcinom* OR adenom*)):ab,ti)) OR (Folfirinox):ab,ti) 
Medline (OvidSP)
((Leucovorin/ AND fluorouracil/ AND irinotecan.mp. AND oxaliplatin.mp. AND Drug 
Combinations/ AND (expPancreatic Neoplasms/ OR (pancrea* ADJ3 (cancer* OR 
neoplas* OR tumo* OR adenocarcinom* OR carcinom* OR adenom*)).ab,ti.)) OR 
(Folfirinox).ab,ti.) 
Cochrane
(Folfirinox):ab,ti
Web-of-science 
TS=(Folfirinox)
Scopus
TITLE-ABS-KEY(Folfirinox)
PubMed publisher 
Folfirinox[tiab] AND publisher[sb]
Google scholar
Folfirinox
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Appendix B 
Excluded studies after full text assessment
1. Paniccia A, Edil BH, Schulick RD, et al: Neoadjuvant FOLFIRINOX application in borderline resectable 
pancreatic adenocarcinoma. Medicine 93, 2014
2. Conroy T, Gavoille C, Samalin E, et al: The role of the FOLFIRINOX regimen for advanced pancreatic 
cancer. Curr Oncol Rep 15:182-189, 2013
3. Nakai Y, Isayama H, Sasaki T, et al: A retrospective analysis of early CA19-9 change in salvage 
chemotherapy for refractory pancreatic cancer. Cancer Chemother Pharmacol 72:1291-1297, 2013
4. Shitara K, Munakata M, Kasai M, et al: Prolongation of survival and improvement in performance status 
following palliative chemotherapy in gastrointestinal cancer patients with a poor performance status. 
Oncology (Switzerland) 74:135-142, 2008
5. Kobayashi N, Shimamura T, Tokuhisa M, et al: Second-line chemotherapy by folfirinox with unresectable 
pancreatic cancer (phase I, II study). Ann Oncol 24:ix47, 2013
6. Tinchon C, Hubmann E, Pichler A, et al: Safety and efficacy of neoadjuvant FOLFIRINOX treatment in a 
series of patients with borderline resectable pancreatic ductal adenocarcinoma. Acta Oncol 52:1231-
1234, 2013
7. Edil BH, Schulick RD, Byers JT, et al: Neoadjuvant FOLFIRINOX Application in Borderline Resectable 
Pancreatic Adenocarcinoma: A Retrospective Cohort Study. Medicine (Baltimore) 93:e198, 2014
8. Christians KK, Tsai S, Mahmoud A, et al: Neoadjuvant FOLFIRINOX for borderline resectable pancreas 
cancer: A new treatment paradigm? Oncologist 19:266-274, 2014
9. Taieb J, Lecomte T, Aparicio T, et al: FOLFIRI.3, a new regimen combining 5-fluorouracil, folinic acid 
and irinotecan, for advanced pancreatic cancer: Results of an Association des Gastro-Enterologues 
Oncologues (Gastroenterologist Oncologist Association) multicenter phase II study. Ann Oncol 18:498-
503, 2007
10. Oh SY, Kim HJ, Kim TH, et al: Pilot study of irinotecan/oxalipltin (IROX) combination chemotherapy for 
patients with gemcitabine- and 5-fluorouracil- refractory pancreatic cancer. Invest New Drugs 28:343-
349, 2010
11. Mazard T, Ychou M, Thezenas S, et al: Feasibility of biweekly combination chemotherapy with 
capecitabine, irinotecan, and oxaliplatin in patients with metastatic solid tumors: results of a two-step 
phase I trial: XELIRI and XELIRINOX. Cancer Chemother. Pharmacol. 69:807-814, 2012
12. Lee MG, Lee SH, Hwang JH, et al: FOLFIRINOX as second-line chemotherapy in patients with advanced 
pancreatic cancer who have progressed on gemcitabine-based therapy. Eur J Intern Med 24:e140, 2013
13. Lee MG, Lee SH, Lee SJ, et al: 5-fluorouracil/leucovorin combined with irinotecan and oxaliplatin 
(FOLFIRINOX) as second-line chemotherapy in patients with advanced pancreatic cancer who have 
progressed on gemcitabine-based therapy. Chemotherapy 59:273-279, 2014
14. Abendroth A, Nourredine R, Abramczyk M, et al: Prognostic factors in patients with pancreatic cancer 
receiving sequential chemotherapies (CTX) at the West German Cancer Center (WTZ), one of the 12 
Oncology Centers of Excellence in Germany. Oncol Res Treat 37:123-124, 2014
15. Anota A, Mouillet G, Trouilloud I, et al: Sequential FOLFIRI.3+Gemcitabine Improves Health-Related 
Quality of Life Deterioration-Free Survival of Patients with Metastatic Pancreatic Adenocarcinoma: A 
Randomized Phase II Trial. PLoS One 10, 2015
16. Nanda RH, El-Rayes B, Maithel SK, et al: Neoadjuvant modified FOLFIRINOX and chemoradiation therapy 
for locally advanced pancreatic cancer improves resectability. J Surg Oncol 111:1028-1034, 2015
17. Yao X, Cong X, Thumar JR, et al: FOLFIRINOX for locally advanced and metastatic pancreatic cancer: 
single institution retrospective review of efficacy and toxicity Review. Med Oncol 30:361, 2013
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Figure 1. Funnel plot of the survival studies.
Two studies are not shown in this funnel plot as Peddi et al. did not reach the median OS and Mellon et al. 
did not have a sufficient number of events to calculate the standard error. Therefore the median OS in this 
funnel plot differ slightly from the pooled analysis.
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Figure 1. Median number of FOLFIRINOX cycles and median OS across studies (p=0·95).
Figure 2. Percentage of (chemo)radiation and median OS across studies (p=0·12).
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FOLFIRINOX and radiotherapy for 
locally advanced pancreatic cancer:  
a cohort study
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Abstract
Introduction: 
One-third of patients with pancreatic cancer present with locally advanced 
unresectable pancreatic cancer (LAPC). Our aim was to determine survival outcomes 
and toxicity after FOLFIRINOX followed by radiotherapy in biopsy-proven LAPC 
patients. 
Methods: 
We analyzed a cohort of biopsy-proven LAPC patients, who were eligible for induction 
FOLFIRINOX (8 cycles) and subsequent radiotherapy (30 fractions, 60 Gray). Eligible 
patients underwent a staging laparoscopy to detect occult metastasis prior to 
treatment. The primary outcome was overall survival (OS) and secondary outcomes 
were progression free survival (PFS), treatment-related toxicity, and resection rate.
Results:
Forty-four patients were diagnosed with biopsy-proven LAPC. Twenty-five patients 
were eligible and all underwent staging laparoscopy prior to treatment. In three 
(12%) patients occult metastases were found. Twenty-two patients started induction 
FOLFIRINOX, 17 (77%) completed all cycles. Seventeen (77%) patients were treated 
with subsequent radiotherapy, with 16 (94%) receiving the full dosage. Three (14%) 
patients underwent a radical resection after treatment. Median OS was 15.4 months 
(95% CI 10.0-20.7), median PFS was 11.0 months (95% CI 7.7 – 14.4). 
Conclusions:
Median OS after FOLFIRINOX and radiotherapy was 15 months in patients with LAPC. 
Toxicity remains severe, however most patients completed all 8 scheduled cycles of 
FOLFIRINOX and radiotherapy.
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Introduction
Pancreatic cancer is the fourth leading cause of cancer-related death, with projections 
to be the second leading cause of cancer-related death in 2030.[1] Pancreatic 
cancer can be divided in three groups: resectable pancreatic cancer (stage I or II; 
15%), locally advanced (unresectable) pancreatic cancer (LAPC) (stage III; 35%), and 
metastatic disease (stage IV; 50%).[2] Resectability of pancreatic cancer is determined 
by the extent of tumor contact with the superior mesenteric artery, coeliac artery, 
common hepatic artery, superior mesenteric vein, and portal vein. There are several 
definitions for resectability, which mainly differ in the extent of vascular tumor 
contact on computed tomography. The Dutch Pancreatic Cancer Group has defined 
LAPC as venous tumor contact exceeding 270 degrees or arterial contact exceeding 
90 degrees (table 1) without distant metastases.[3] The initial treatment for LAPC 
is systemic chemotherapy.[4] FOLFIRINOX (leucovorin, fluorouracil, irinotecan, and 
oxaliplatin) is the preferred treatment, based upon the results of a randomized study 
showing a significant and relevant improvement in OS compared to gemcitabine in 
patients with metastatic disease (median OS 11.1 versus 6.8 months, p<0.0001).[5] 
No randomized trials have been published on FOLFIRINOX in patients with LAPC. 
However, several case series have shown favorable survival with a median OS ranging 
from 10.0 to 32.7 months.[6] Patients who do not develop metastatic disease during 
FOLFIRINOX may benefit from subsequent radiotherapy for local control.[4] 
 The objective of this study was to assess survival outcomes and toxicity of 
FOLFIRINOX followed by radiotherapy in patients with LAPC. 
Methods
Between January 2012 and December 2014, all consecutive patients diagnosed with 
biopsy-proven LAPC who received induction FOLFIRINOX at the Erasmus MC Cancer 
Institute (EMC) were enrolled in a local database. No informed consent was obtained 
from the patients during this period as the standard local treatment was induction 
FOLFIRINOX followed by radiotherapy. Furthermore, all patients that had biopsy 
proven LAPC but did not receive the FOLFIRINOX treatment in the same period were 
retrospectively identified by searching the local review board meeting reports. LAPC 
was defined as tumor contact with the superior mesenteric artery (SMA), coeliac 
artery, or common hepatic artery exceeding 90 degrees or contact with the superior 
mesenteric vein or portal vein exceeding 270 degrees on computed tomography (CT) 
scan, in the absence of metastatic disease.[3]
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Table 1. Baseline characteristics.
FOLFIRINOX (N=22) No FOLFIRINOX (N=19) p=
Age, median [IQR] 62 [52-67] 62 [53-67] 0.33
Gender
Male
Female
6
16
7
12
0.74
WHO
0-1
2-4
22
0
9
10
<0.001
Jaundice 
Yes
No
9
13
9
10
0.76
Weight loss 
Yes
No
15
7
14
5
0.74
Diabetes 
Yes
No
4
18
4
15
1.00
Abdominal pain 
Yes
No
21
1
17
2
0.59
BMI, median [IQR] 23 [22-25] 23 [20-28] 0.90
Tumor origin
Head
Body
Tail
13
9
0
12
5
2
0.23
Median CA 19.9 309 [105-912] 560 [167-744] 0.88
Median CEA 3.5 [2.4-12.2] 3.4 [2.2-4.1] 0.50
Maximum tumor size (mm), median [IQR] 36 [30-43] 35 [23-40] 0.37
Locally advanced based on
Only arterial
Only venous 
Both arterial and venous
7
5
10
9
4
6
0.35
1.00
0.52
 Patients were eligible for FOLFIRINOX and radiotherapy if they had a World 
Health Organization (WHO) Performance status of 0 or 1, and were not older than 
75 years old. The diagnostic work-up of patients with suspicion of LAPC consists 
of a computed tomography (CT) scan of the thorax, abdomen, and pelvis.[4] 
Histopathological diagnosis of pancreatic cancer was confirmed with biopsy by 
endoscopic ultrasound in all patients. After confirmation of the diagnosis, a staging 
laparoscopy was performed to exclude occult metastases. FOLFIRINOX treatment 
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was started within 4 weeks after staging laparoscopy in all patients. The dose of 
FOLFIRINOX was according to the PRODIGE 4 trial, consisting of a 2-h intravenous 
infusion of oxaliplatin (85 mg/m²) followed by a 2-h intravenous infusion of leucovorin 
(400 mg/m²) concomitantly with a 90-min intravenous infusion of irinotecan 
(180 mg/m²), followed by a bolus (400 mg/m²) and a 46-h continuous infusion 
(2400 mg/m²) of fluorouracil.[5] The duration of a cycle was 2 weeks.(7) Patients were 
scheduled for 8 cycles of FOLFIRINOX. Surveillance imaging was performed after 
4 and 8 cycles of FOLFIRINOX with a tri-phase abdominal CT scan. Treatment was 
terminated if progression (according to RECIST 1.1) was seen.[8] Patients who had 
stable disease or partial response received radiotherapy after 8 cycles of FOLFIRINOX 
or earlier if the FOLFIRINOX treatment was discontinued because of toxicity. Dose 
reduction of 25% were applied if there were serious adverse events related to one of 
the components of FOLFIRINOX. Chemotherapy was discontinued if toxicity persisted 
after the second dose reductions. Radiotherapy consisted of 2 Gy per fraction to a 
total dose of 60 Gy. After radiotherapy, again a tri-phase CT-scan was performed 
and patients were considered in a multidisciplinary review board for curative-intent 
resection. Adverse events were graded using National Cancer Institute (NCI) Common 
Toxicity Criteria (CTC 4.0). 
 Overall survival (OS) was calculated from the start of the FOLFIRINOX treatment 
to the date of death. Progression free survival (PFS) was calculated from the start 
of FOLFIRINOX treatment to the date of progression or death. For the patients who 
did not receive FOLFIRINOX, OS was calculated from the date of histopathological 
confirmation of LAPC until progression or death. Survival functions were estimated 
using the Kaplan-Meier method in SPSS (version 21). 
Results
During the study period, 44 patients presented with biopsy-proven LAPC (figure 1). 
Nineteen patients (12 (60%) female, median age 62 years) were not included due 
to either poor condition (WHO performance status 2-4 condition) (n=10), patient 
preference (n=6), and no staging laparoscopy performed prior to treatment (n=4). 
These four patients received chemotherapy treatment in other hospitals. A total of 25 
patients were enrolled and underwent a staging laparoscopy. In three patients (12%) 
occult peritoneal metastases were identified. In total, 22 patients were scheduled for 
FOLFIRINOX and RT; the remaining 19 patients received FOLFIRINOX in other hospitals, 
gemcitabine or best supportive care. Baseline patient and tumor characteristics were 
similar between the FOLFIRINOX with RT group versus other LAPC patients, except for 
the high rate of poor performance status in the latter (table 1). 
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Figure 1. Flowchart of the study population.
Patients that were eligible for the standard care received a median of 8 cycles of 
FOLFIRINOX (range 2-9), with 4 (18%) patients receiving less than 5 cycles and 18 (82%) 
patients receiving at least 7 cycles. The reasons for termination of the FOLFIRINOX 
after less than 5 cycles were toxicity in 3 (14%) patients and distant progressive 
disease in 1 (5%) patient. A dose reduction was required for 8 (36%) patients, with 
7 patients receiving 75% and 1 patient 50% of the prescribed dose. No recombinant 
human granulocyte colony-stimulating factor (GCSF) analogs were prescribed for any 
patients during the treatment. One patient (5%) had a partial radiological response, 
19 (83%) stable disease, and 2 (9%) patients progressive disease after FOLFIRINOX 
treatment.
 Five (23%) patients of the 22 did not receive radiotherapy due to deterioration of 
patients’ condition(n=3), distant progressive disease under FOLFIRINOX (n=2). The 
remaining 17 (77%) patients received radiotherapy; 16 (94%) received the full dose 
of 60 Gray and only 1 (6%) patient received 52 Gray due to the patient’s condition. 
One (6%) patient had a partial response, 11 (65%) patients stable disease, and 5 (29%) 
patients progressive disease. The progression was seen both local and distant in three 
(60%) patients, and only distant in two (40%) patients.
 At last follow-up, all 22 patients died of progressive disease. The median PFS and 
OS of the group “protocolled FOLFIRINOX” (n=22) was 11.0 months (95% CI 7.7 – 14.4) 
and 15.4 months (95% CI 10.0-20.7), respectively (figure 2). The actual 1-year survival 
Biopsy-proven LAPC 
(n=45)
Staging laparoscopy 
(n=26)
Protocolled  
FOLFIRINOX (n=22)
No protocolled 
FOLFIRINOX (n=19)
WHO PS 2-4 (n=10)
Patient preference  
(n=5)
No staging 
laparopscopy (n=4)
Occult metasasis (n=3)
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rate was 68% (95% CI 47% – 84%), and the actual 2-years survival rate was 14% (95% 
CI 5% - 33%). The median OS after completion of both FOLFIRINOX and radiotherapy 
(n=17) was 18.7 months (95% CI 13.4 -23.9). The median OS of “protocolled 
FOLFIRINOX” (n=22) from date of histopathological confirmation until date of death 
was 16.3 months (95% CI 11.4 – 21.2). In comparison, the patients that did not receive 
protocolled FOLFIRINOX and radiotherapy (n=19) all died and had a median OS of 6.2 
months (95% CI 3.8 – 8.5) with actual 1-year OS of 37% (95% CI 19% - 59%) and actual 
2-year OS of 5% (95% CI 9% - 25%).
Figure 2. Kaplan-Meier curves of OS and PFS for the patients treated with FOLFIRINOX.
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 There were 13 (59%) grade 3 or 4 adverse events seen in 13 patients, including 
diarrhea (n = 4), elevated liver enzymes (n = 3), neutropenic fever (n = 1), nausea 
(n = 1), mucositis (n =1 ), fatigue (n = 1), gastro-intestinal bleeding (n=1), and ascites 
(n = 1). All serious adverse events of the FOLFIRINOX treatment are summarized in 
table 3. No deaths were attributed to FOLFIRINOX. Only 1 (6%) patient had a serious 
adverse event of grade 3 of diarrhea during radiotherapy.
 Three (14%) patients underwent an exploratory laparotomy patients after 
FOLFIRINOX and radiotherapy. One (5%) patient was found to have peritoneal 
metastasis at exploratory laparotomy and underwent a gastric bypass. Two (9%) 
patients underwent a curative-intent resection; modified Appleby resection, and one 
a distal pancreatectomy. All two (100%) resections were radical (R0, closest margin 
> 1mm). Survival time after resection was 16 and 10 months in two patients with a 
partial response in histopathological examination. 
Table 2. Serious adverse events during FOLFIRINOX, n=13.
Description Grade 3 Grade 4
Diarrhea 4 0
Elevated ALT/AST 1 2
Neutropenic fever 1 0
Ascites 1 0
Fatigue 1 0
GI bleeding 0 1
Mucositis 1 0
Nausea 1 0
Paresthesia 0 0
Total 10 3
GI: gastro-intestinal, ALT: alanine transaminase, AST: aspartate transaminase
Discussion
In this cohort study, 22 patients with LAPC received FOLFIRINOX with subsequent 
conventional radiotherapy. The median OS was 15 months and the PFS 11 months. 
Most patients (77%) completed both chemotherapy and radiotherapy. No mortality 
was attributed to the treatment, but 64% had at least one grade 3 or 4 toxicity. 
Nineteen patients with LAPC did not receive the protocolled care for various reasons 
resulting in a median OS of 6.2 months. 
 Since the randomized controlled trial conducted by Conroy et al.[5] showed a 
survival benefit for FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer, 
many case series were published that evaluated the survival effect of FOLFIRINOX 
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for patients with LAPC.[9-20] However, no randomized controlled trials are published 
that confirmed a survival benefit of FOLFIRINOX in LAPC patients. A recent patient-
level meta-analysis of 315 LAPC patients treated with first-line FOLFIRINOX showed a 
median OS of 24.2 months and PFS of 15.0 months.[6]
 Our median OS and PFS is lower than found in the meta-analysis. However, most 
studies in the meta-analysis were retrospective, which may cause selection bias. On 
the other hand, we used staging laparoscopy prior to treatment to rule out occult 
metastatic disease. This approach is based upon two studies that have shown that 
34% and 35% of patients with LAPC are found to have clinically and radiographically 
undetermined metastatic disease during staging laparoscopy.[21, 22]
 The FOLFIRINOX treatment toxicity of 59% serious adverse events is comparable 
to the other studies published about this treatment regimen, with the meta-analysis 
showing a 60% of serious adverse events during the treatment. Despite this high 
toxicity profile, FOLFIRINOX showed a better quality of life than gemcitabine in the 
PRODIGE 4 trial, probably by deferring definitive deterioration.[23]
 Radiotherapy had a very low rate of serious adverse events (6%) in our study and 
therefore is safe to give as subsequent treatment after first-line FOLFIRNOX. However, 
whether conventional radiotherapy improves survival for LAPC patients has not been 
evaluated in a randomized controlled trial.[4] In regard of chemoradiotherapy, in 2016 
Hammel et al. published the LAP07 randomized controlled trial which randomized 
patients with LAPC for induction chemotherapy (gemcitabine vs. gemcitabine and 
erlotinib) followed by a second randomization of continuing chemotherapy versus 
chemoradiotherapy (54 Gy plus capecitabine).[24] During the interim analysis the 
study was stopped as it reached the early stopping boundaries for futility. However, 
the study did not show a significant median overall survival benefit between 
continuing chemotherapy or subsequent chemoradiotherapy after induction 
chemotherapy with a median survival of 16.5 versus 15.2 months respectively. The 
major disadvantage of conventional fractionated radiotherapy for pancreatic cancer 
is that although the pancreas is relatively radioresistant the surrounding organs are 
highly radiosensitive.[25] In the last years stereotactic body radiotherapy (SBRT) has 
emerged as the preferred radiotherapy after systemic chemotherapy for LAPC. SBRT 
allows for a higher dose of radiotherapy to the pancreatic tumor with less radiation to 
the surrounding organs.[26] A low rate of serious adverse events (7%) was also seen 
by Mellon and colleagues when SBRT was given as therapy for borderline resectable 
and locally advanced pancreatic cancer after induction chemotherapy.[27]
 In our study, two (9%) patients underwent a resection with, both being a radical 
resection. This rate was lower than the pooled resection rate of 28% shown in the 
meta-analysis.[6] In our clinic the decision to do an exploration after induction therapy 
is based on the same definitions for LAPC. So arterial tumor encasement should not 
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exceed 90 degrees and venous encasement not exceed 270 degrees. These more 
conservative criteria for exploration could have led to a lower resection rate than 
given in other studies. Furthermore, the meta-analysis did not detect an association 
between a studies resection rate and survival. Some studies report remarkable 
survival outcomes in LAPC patients after induction FOLFIRINOX and resection. 
However, these patients are highly selected and the favorable outcomes may be 
largely attributable to guaranteed-time bias.[28, 29] The most recent ASCO guideline 
advices that all patients with LAPC should receive first-line chemotherapy with or 
without radiotherapy and surgery should be only considered if dramatic response 
to induction therapy was achieved.[4] In our clinic the decision to do an exploration 
after induction therapy is based on the same definitions for LAPC. So arterial tumor 
encasement should not exceed 90 degrees and venous encasement not exceed 270 
degrees. These more conservative criteria for exploration could have led to a lower 
resection rate than given in other studies. Future studies should determine which 
patients could potentially benefit from a resection after induction chemotherapy. 
 Our study has several limitations. The main limitation is that the sample size of 
patients that received full treatment is small to draw definitive conclusions. However 
despite the small sample size, this study gives an overview of how many patients 
eventually receive induction chemotherapy after the diagnosis of LAPC. Furthermore, 
there is no general consensus in the definition for LAPC that can help generalize 
the interpretation of different treatment regimens. Although, the Dutch Pancreatic 
Cancer Group definitions for LAPC are more conservative than the most commonly 
used definitions such as NCCN and AHPBA/SSO/SSAT definitions[30, 31], there is no 
evidence that there is a difference in survival because of these criteria. Additionally, 
conventional radiotherapy was used in this study while SBRT can maybe induce a 
better local control as mentioned above.
 In conclusion, this study gives an overview of the current practice and strategy 
of patients with LAPC in the Netherlands. FOLFIRINOX followed by radiotherapy can 
be offered to a limited number of patients but it could be considered as safe and 
shows promising survival results for patients with LAPC. Randomized controlled 
trials are needed to determine the value of radiotherapy, and resection in addition to 
FOLFIRINOX in patients with LAPC.
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Pancreatic cancer is divided in four stages: resectable, borderline resectable, locally 
advanced, or metastatic disease.[1] Locally advanced pancreatic cancer (LAPC) 
comprises one-third of the patients diagnosed with pancreatic cancer.[2] Staging of 
LAPC is based on computed tomography (CT) of chest, abdomen and pelvis.[3] Some 
centers perform a staging laparoscopy in the diagnostic work-up of LAPC. However, 
there is no consensus on the role of staging laparoscopy in the diagnostic work-up 
of LAPC.[1, 4]
 In the past, LAPC patients were usually studied together with metastatic 
pancreatic cancer and are often referred as advanced pancreatic cancer patients.[5] 
Currently, there are some advances in the treatment of pancreatic cancer, with new 
chemotherapeutic combinations, and new local ablative therapies.[6-8] This has led 
to a new interest in LAPC, as combination therapy with systemic and local therapies is 
hypothesized to improve survival of these patients.[9] As a result, LAPC has emerged 
as a distinct patient population, mainly due to the evolution in local therapies. 
 In the last decade, FOLFIRINOX has emerged as a new combination chemotherapy. 
Several cohort studies show promising survival data for LAPC patients.[10] If 
progression is halted by systemic chemotherapy, radiotherapy is indicated for LAPC.
[3] Nowadays, stereotactic body radiotherapy (SBRT) is considered as alternative to 
conventional radiotherapy for local ablative treatment in LAPC.[11]
 In this thesis, we aimed to optimize the staging of LAPC, and examined the 
potential survival benefit of FOLFIRINOX in combination with radiotherapy. 
Part I: Staging of LAPC
The National Comprehensive Center Network (NCCN) recommend routine chest 
CT-scans in pancreatic cancer. However, many centers do not perform these scans 
routinely for (borderline) resectable pancreatic cancer, as it has no influence on 
survival.[12] There are no studies addressing the clinical value of follow-up chest CT-
scans in patients with LAPC. In chapter 2, we describe the findings of chest CT-scans 
in 119 LAPC patients. On first staging chest CT-scans, 13% of the patients showed 
pulmonary nodules too small to characterize. In follow-up chest CT-scans, available 
in 111 patients, only 4% of the patients showed malignant-appearing pulmonary 
nodules. All these malignant pulmonary nodules were seen as nodules too small 
to characterize on first staging chest CT-scan. Notably, no difference in treatment 
management or survival was found between patients with and without nodules too 
small to characterize on first staging chest CT-scan. 
 In the past, staging laparoscopy has been reported to upstage one-third of LAPC 
patients to metastatic disease.[13, 14] In chapter 3, we evaluated the current yield of 
staging laparoscopy for occult metastasis in LAPC. Ninety-one patients underwent a 
staging laparoscopy after diagnosed with biopsy-proven LAPC. The yield of staging 
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laparoscopy for metastasis was 19% (95% CI: 12 - 28). Only serum tumor marker CEA 
appeared to be a significant preoperative predictor for occult metastasis found with 
staging laparoscopy (OR 1.056, 95% CI: 1.007 - 1.107, p=0.02). There was no significant 
1-year survival rate difference between patients with and without occult metastasis 
(29% vs. 53%, p=0.11).
Part II: Treatment of LAPC
In 2011, FOLFIRINOX was introduced as the standard first-line chemotherapy for 
patients with metastasized pancreatic cancer.[15] Since then, many cohort studies 
have been published, evaluating the efficacy of FOLFIRINOX in the LAPC setting. 
In chapter 4, we conducted a systemic review and a patient-level meta-analysis, 
reviewing the findings of these cohort studies. A total of 11 studies, comprising 315 
patients with LAPC, were included in the patient-level meta-analysis. The pooled 
patient-level median overall survival (OS) was 24 months (95% CI: 22 – 27), while the 
pooled patient-level median progression free survival (PFS) was 15 months (95% CI: 
14 – 16). The pooled proportion of patients who received radiotherapy treatment was 
64% (95% CI: 43 – 82), while the pooled proportion of patients who had resection 
was 26% (95% CI: 20 – 32). A radical resection was achieved in 79% of the patients 
(95% CI: 60 – 92). There was no significant association between receiving subsequent 
radiotherapy and OS (p=0.12). Additionally, there was no significant association 
between resection rate and OS (p=0.39). 
 Between 2012 and 2014, all patients with LAPC seen at Erasmus MC, were offered 
FOLFIRINOX with subsequent conventional radiotherapy. Chapter 5 presents 
the results of the patients that were eligible for this protocol. In total, 22 patients 
started the FOLFIRINOX treatment. Subsequent radiotherapy was given in 77% of the 
patients. A radical resection was achieved in 14% of the patients. Median OS was 15 
months (95% CI: 10 - 20) for the entire cohort, while median PFS was 11 months (95% 
CI: 8 – 14). 
 Subsequent to this cohort, we present in a multicenter phase II trial was conducted 
to investigate the feasibility and efficacy of sequential FOLFIRINOX and SBRT in LAPC 
patients. Patients received 8 cycles of FOLFIRINOX. If no tumor progression after the 
FOLFIRINOX treatment was observed, SBRT (5 fractions/8Gray) was given. Resection 
was considered if downstaging of the tumor was seen on imaging. In chapter 6 
we discuss the findings of this trial. From 2015 till 2017, a total of 50 patients were 
included in the final analysis and started the FOLFIRINOX treatment. SBRT was given 
in 78% of the patients, with eventually in 12% of patients a radical resection was 
achieved. In 4% of the patients, a complete pathological response was seen. In total, 
30 grade 3 or 4 events were seen during the FOLFIRINOX treatment. While after SBRT, 
a grade 3 or 4 adverse events was seen in 5% of the patients, and a grade 5 adverse 
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event was seen in 5% of the patients. For the whole cohort, the median OS and PFS 
were 15 (95% CI: 11 - 18) and 9 months (95% CI: 8 - 10), respectively. The median OS for 
patients who had completed SBRT was 17 months (95% CI: 14 - 21) versus 7 months 
(95% CI: 6 - 8) in patients who had not received SBRT (p<0.001). Median locoregional 
PFS in all patients was 17 months (95% CI 11-24), 20 months (95%: CI 14 - 28) for the 
SBRT group and 3 months (95% CI: 2 - 4) for the non-SBRT group (p<0.001). The median 
distant PFS in all patients was 11 months (95% CI: 10 - 12), for the SBRT group 11 months 
(95% CI: 9 - 13), and 3 months (95% CI: 2 - 4) in the non SBRT group (p<0.001).
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Samenvatting
Alvleesklierkanker wordt onderverdeeld in vier stadia: resectabel, borderline 
resectabel, lokaal irresectabel of gemetastaseerde ziekte.[1] Lokaal irresectable 
alvleesklierkanker (LAPC) omvat één derde van de patiënten.[2] Stagering van 
LAPC is gebaseerd op computertomografie (CT) van de thorax, de abdomen en het 
bekken.[3] Sommige centra includeren ook een diagnostische laparoscopie voor de 
stagering van LAPC. Echter, momenteel bestaat er geen consensus over de rol van 
diagnostische laparoscopie in de diagnostiek van LAPC.[1, 4] 
 In het verleden werd er geen onderscheid gemaakt tussen LAPC-patiënten 
en patiënten met gemetastaseerde ziekte. Beide groepen werden aangeduid 
als patiënten met gevorderde alvleesklierkanker.[5] In de afgelopen jaren zijn 
er veel vorderingen gemaakt in de behandeling van alvleesklierkanker. Nieuwe 
chemotherapeutische combinaties worden onderzocht en nieuwe lokale ablatieve 
therapieën zijn ontwikkeld.[6-8] Deze ontwikkeling heeft geleid tot een nieuwe 
interesse in LAPC, aangezien verondersteld wordt, dat een combinatietherapie 
bestaande uit systemische en lokale therapie, de overleving van LAPC-patiënten 
zou moeten verbeteren.[9] Als gevolg van de ontwikkelingen binnen de lokale 
therapieën, worden LAPC patiënten sinds kort als een aparte groep beschouwd. 
 In het laatste decennium is FOLFIRINOX naar voren gekomen als een nieuwe 
potentiële combinatiechemotherapie. De resultaten met betrekking tot de overleving 
in LAPC-patiënten zijn veelbelovend. [10] Indien systemische chemotherapie 
tumorprogressie remt, is aanvullend radiotherapie aanbevolen in LAPC patiënten.
[3] Momenteel is er veel aandacht voor stereotactische radiotherapie (SBRT) als een 
alternatief voor de conventionele radiotherapie in de LAPC-setting. [11]
 In dit proefschrift focussen wij ons op het optimaliseren van de stadiëring van 
LAPC-patiënten en onderzoeken wij het potentiële overlevingsvoordeel van 
FOLFIRINOX in combinatie met radiotherapie. 
Deel I: stadiëring van LAPC 
Het National Comprehensive Center Network (NCCN) adviseert routinematige 
thorax-CT-scans bij patiënten met alvleesklierkanker. Echter, veel centra voeren deze 
scans niet routinematig uit voor (borderline) resectabele alvleesklierkanker, omdat 
het geen invloed heeft op de overleving.[12] Tot op heden zijn er geen studies die 
de klinische meerwaarde van follow-up thorax CT-scans in patiënten met LAPC 
beschrijft. 
 In hoofdstuk 2 beschrijven wij de bevindingen van thorax CT-scans bij 119 LAPC-
patiënten. Op de eerste CT-scan liet 13% van de patiënten een pulmonale nodus zien 
die te klein was om te karakteriseren. Van 111 patiënten was de follow-up CT-scan 
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beschikbaar, waarvan slechts 4% een maligne pulmonale nodus liet zien. Al deze 
maligne pulmonale noduli waren te klein op de eerste CT-scan om te karakteriseren. 
Er werd geen verschil in behandeling of overleving gevonden tussen patiënten met 
en zonder pulmonale noduli die te klein waren om te karakteriseren op de eerste CT-
scan.
 In het verleden is gerapporteerd dat diagnostische laparoscopie een derde van 
de LAPC-patiënten alsnog als metastatische ziekte stadieert.[13, 14] In hoofdstuk 
3 evalueren we de huidige opbrengst van diagnostische laparoscopie voor occulte 
metastasen in LAPC. In totaal ondergingen 91 patiënten een diagnostische 
laparoscopie nadat de diagnose van LAPC met een biopsie was bevestigd. De 
opbrengst van diagnostische laparoscopie voor metastase was 19% (95% CI: 12 - 28). 
Alleen serumtumormarker CEA bleek een significante preoperatieve voorspeller te 
zijn voor occulte metastasen (OR 1.056, 95% CI: 1.007 - 1.107, p = 0.02). Er was geen 
significant verschil in overlevingspercentage van 1 jaar tussen patiënten met en 
zonder occulte metastasen (29% vs. 53%, p = 0.11).
Deel II: Behandeling van LAPC 
In 2011 werd FOLFIRNOX geïntroduceerd als de standaard eerstelijns chemotherapie 
voor patiënten met gemetastaseerd alvleesklierkanker.[15] Sindsdien zijn er veel 
studies gepubliceerd, waarbij de effectiviteit van FOLFIRINOX in de LAPC-setting 
werd geëvalueerd. 
 In hoofdstuk 4 hebben wij een systematische review en een meta-analyse op 
patiëntniveau uitgevoerd en beschrijven wij de bevindingen van deze cohortstudies. 
In totaal zijn er 11 studies, bestaande uit 315 patiënten met LAPC, geïncludeerd 
in de individuele patiëntniveau meta-analyse. De mediane overall survival (OS) op 
patiënt niveau was 24 maanden (95% CI: 22 - 27), waar de mediane progression free 
survival (PFS) 15 maanden was (95% CI: 14 - 16). Het gepoolde aantal patiënten dat 
radiotherapie ontving was 64% (95% CI: 43 - 82), terwijl het gepoolde percentage 
van de patiënten met resectie 26% was (95% CI: 20 - 32). Een radicale resectie was 
uitgevoerd in 79% van de patiënten (95% CI: 60 - 92). Er was geen significant verband 
tussen behandeling met radiotherapie en de OS (p = 0.12). Daarnaast was er ook 
geen significant verband tussen de resectie ratio en OS (p = 0.39).
 Tussen 2012 en 2014 kregen alle patiënten met LAPC in Erasmus MC, FOLFIRINOX 
aangeboden met aanvullend conventionele radiotherapie. Hoofdstuk 5 beschrijft 
de resultaten van de patiënten die in aanmerking kwamen voor dit protocol. In 
totaal waren er 22 patiënten gestart met FOLFIRINOX behandeling. Aanvullende 
radiotherapie werd gegeven bij 77% van de patiënten. Een radicale resectie werd 
bereikt in 14% van de patiënten. Voor de totale cohort was de mediane OS en PFS 15 
maanden (95% CI: 10 - 20) en 11 maanden (95% CI: 8 - 14) respectievelijk. 
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 Als vervolg op deze studie, hebben wij een multicenter fase II-studie opgezet om de 
haalbaarheid en effectiviteit van FOLFIRINOX met aanvullende SBRT te onderzoeken 
in LAPC-patiënten. Patiënten werden behandeld met 8 cycli FOLFIRINOX. Indien er 
geen tumorprogressie werd waargenomen na de behandeling met FOLFIRINOX, was 
SBRT (5 fracties/ 8 Gray) geïndiceerd. Chirurgische resectie werd overwogen indien 
de tumor op beeldvorming als resectabel werd geacht. In hoofdstuk 6 bespreken 
we de bevindingen van deze studie. Van 2015 tot 2017 werden in totaal 50 patiënten 
geïncludeerd en behandeld met FOLFIRINOX. Aanvullend werd SBRT gegeven bij 
78% van de patiënten, waarbij uiteindelijk bij 12% van de patiënten een radicale 
resectie werd bereikt. In 4% van de gevallen werd een complete pathologische 
response gezien. In totaal werden er 30 graad 3 of 4 adverse events gezien tijdens de 
behandeling met FOLFIRINOX. In 5% van de gevallen trad graad 3 of 4 adverse events 
op na SBRT, waarbij in 5% van de patiënten een graad 5 adverse event werd gezien. 
Voor de totale cohort was de mediane OS en PFS 15 (95% CI: 11 - 18) en 9 maanden 
(95% CI: 8 - 10), respectievelijk. De mediane OS voor patiënten die SBRT hadden 
gekregen was 17 (95% CI: 14 - 21) versus 7 maanden (95% CI: 6 - 8) bij patiënten 
die geen SBRT hadden ontvangen (p<0.001). De mediane locoregionale PFS bij alle 
patiënten was 17 maanden (95% CI 11-24), waarvan 20 maanden (95%: CI 14 - 28) 
voor de SBRT-groep en 3 maanden (95% CI: 2 - 4) voor de niet-SBRT groep (p <0.001). 
De mediane afstands PFS bij alle patiënten was 11 maanden (95% CI: 10 - 12), voor de 
SBRT-groep 11 maanden (95% CI: 9 - 13) en 3 maanden (95% CI: 2-4) in de niet-SBRT-
groep (p<.001).
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Part I: Staging of LAPC
The two most commonly used definitions for (borderline) resectable disease and 
locally advanced disease are defined by the National Comprehensive Cancer (NCCN) 
and the combined definition of Americas Hepato-Pancreato-Biliary Association 
(AHPBA), the Society of Surgical Oncology (SSO), and the Society for Surgery of the 
Alimentary Tract (SSAT).[1, 2] In the Netherlands, the definitions for locally advanced 
pancreatic cancer (LAPC) is defined by the Dutch Pancreatic Cancer Group (DPCG). 
Their definition is tumor contact with the arteries superior mesenteric artery (SMA), 
coeliac artery (CA), or common hepatic artery (CHA) exceeding 90 degrees or contact 
with the veins superior mesenteric vein (SMV) or portal vein (PV) exceeding 270 
degrees.[3] The DPCG definition for LAPC is more conservative than the NCCN and 
AHPBA/SSO/SSAT definitions. Patients considered as LAPC in the Netherlands could 
be defined as borderline resectable in the USA. There is a need for a worldwide 
consensus on the definition for LAPC. This could not only improve the generalizability 
of future studies on this subject, but also give more insight in the tumor biology of 
LAPC. 
 The NCCN guidelines recommend a staging chest, abdomen and pelvic CT-
scan in pancreatic cancer.[4] However, many centers do not perform routine chest 
CT-scans in (borderline) resectable pancreatic cancer patients.[5] This is based on 
several studies reporting that chest CT-scans have limited implication on treatment 
management and survival of patients with (borderline) resectable pancreatic 
cancer.[6-8] In patients with LAPC, chest CT-scan could also be questioned, as our 
study showed that only in a few patients pulmonary nodules could be considered 
as malignant in follow-up CT-scans. Moreover, all these nodules were first seen as 
indefinite pulmonary nodules on first staging CT-scan. These indefinite pulmonary 
nodules impose a clinical dilemma, with a potential burden for the patient because 
of invasive diagnostic tests and delay of treatment. For example, transthoracic lung 
biopsies of small pulmonary nodules can cause a considerable risk of pneumothorax 
or intrathoracic bleeding.[9] For treatment monitoring purposes, follow-up chest 
CT-scans can be considered in patients with indefinite pulmonary nodules on first 
staging CT-scan. However, there is a need for more studies to confirm our findings, 
as our study is the first that examined the clinical value of chest CT-scans in patients 
with LAPC. 
 A consensus report by the AHPBA published in 2009 recommends staging 
laparoscopy in patients with LAPC.[2] This recommendation is based on two studies, 
in which the yield of staging laparoscopy in patients with LAPC was about 35%.[10, 11] 
The AHPBA consensus states that staging laparoscopy could serve for two essential 
purposes. First, it eliminates the cost, inconvenience, and potential morbidity of 
radiotherapy. Second, it allows for better understanding of new treatment protocols 
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since patients with understaged disease are excluded before diluting true outcomes. 
However, in recent years, the imaging modalities have improved considerably. Despite 
the advanced in clinical diagnostics with specialized radiologist and multimodality 
review boards, our data still showed that the yield of staging laparoscopy for occult 
metastasis is about 20% in patients with LAPC. We advocate that staging laparoscopy 
should be included in the diagnostic work-up voor LAPC. By finding these occult 
metastasis, futile local therapies could be avoided. However, the timing of the staging 
laparoscopy is still debatable. For study purposes, we recommend to perform a staging 
laparoscopy before any treatment. In this way, patient selection is standardized and 
data can be generalized. Patients with occult metastasis who have partial response 
can be seen as false negative for occult metastasis during staging laparoscopy. This 
might not be an issue in clinical practice, as these patients might benefit from local 
therapy as well. Unfortunately, only limited data have been published on the role of 
staging laparoscopy in LAPC setting.[12] Therefore, no definite conclusions can be 
made on the timing of staging laparoscopy in patients with LAPC. 
Part II: Treatment of LAPC
The current treatment in patients with LAPC is systemic chemotherapy.[4] In 2011 an 
RCT was conducted by Conroy et al. with FOLFIRINOX versus gemcitabine for patients 
with metastatic and locally advanced pancreatic cancer.[13] Afterwards, many case 
series have been published with FOLFIRINOX as first-line treatment for LAPC.[14] In 
this thesis, a patient-level meta-analysis of comprising 315 patients with LAPC treated 
with first-line FOLFIRINOX showed a median OS of 24 months.[14] Strikingly, this 
median OS was comparable to patients with BRPC receiving neoadjuvant FOLFIRINOX 
treatment.[15] However, this median OS found in the patient-level meta-analysis for 
patients with LAPC should be interpreted with caution. This relatively high survival 
seen after FOLFIRINOX could be influenced by patients selection and publication bias. 
In our study, patients with LAPC were treated with induction FOLFIRINOX followed by 
conventional radiotherapy. Twenty-two patients were included in this cohort, which 
showed a median OS of 15 months.[16] The lower median OS found in our cohort 
compared to the meta-analysis could be explained by the prospective nature of our 
cohort. Although there is no level 1 evidence for the best chemotherapy to use in 
LAPC, FOLFIRINOX seems to be the most potent chemotherapy.[4, 17] Despite the 
fact that FOLFIRINOX has a higher toxicity rate than gemcitabine, the quality of life 
of patients with metastatic pancreatic cancer receiving FOLFIRINOX is significantly 
better than those receiving gemcitabine.[18] Therefore, for patients with a good 
performance state we recommend FOLFIIRNOX as first choice of therapy. Alternatives 
are Nab-paclitaxel-gemcitabine or gemcitabine as first-line treatment.[4] Hopefully, 
the French trial NEOPANC which randomizes patients with LAPC between FOLFIRINOX 
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and gemcitabine can give more definite answers on the best chemotherapy in the 
LAPC setting (ClinicalTrials.gov Identifier: NCT02539537).
 Subsequent local (chemo)radiotherapy after induction chemotherapy is 
recommended in patients with LAPC without any evidence of systemic disease.[4, 19] 
The main goal of radiotherapy is to delay or prolong local progression. So far, there 
is no clear evidence which radiotherapy is the best in the LAPC setting.[4] In the last 
decade, stereotactic body radiotherapy (SBRT) is of interest decade, as it can give 
higher dosage of radiotherapy with more precision. This could inflict more destruction 
to the tumor, with less scattering to surrounding organs.[20, 21] We conducted 
a phase II trial to evaluate the efficacy and feasibility of SBRT after FOLFIRINOX 
treatment in patients with LAPC. Of the 50 patients that received FOLFIRINOX, 
eventually 39 patients underwent SBRT. The median OS of the patients receiving 
SBRT was 17 months. While the median locoregional progression free survival (PFS) 
was 20 months after SBRT, the median distant PFS was 11 months. Strikingly, systemic 
control remains the biggest obstacle in the treatment of LAPC, while the local control 
can be achieved by multimodality treatment. These findings underline the systemic 
nature of pancreatic cancer. Therefore, new studies should focus on systemic control 
of LAPC. A possibility is to restart chemotherapy after radiotherapy. However, second-
line chemotherapy could have a high burden on a patient as it could be associated 
with cumulative toxicity.[19] Evermore, Tsang et al. showed that second-line therapy 
can only be given for a short period of time in advanced pancreatic cancer.[22] 
Therefore, new innovative systemic therapies are urgently needed in pancreatic 
cancer. Immunotherapy is emerging as a new possible synergetic treatment to 
radiotherapy.[23, 24] There are some indications that radiotherapy in pancreatic 
cancer can induce an abscopal effect.[25] The combination of radiotherapy with 
anticancer vaccines and checkpoint inhibitors have an in increase in response rates 
in preclinical trials.[26] The rationale for this treatment regimen is the induction of 
tumor damage and cell apoptosis by radiotherapy, immunotherapy could boost the 
immune system to start a chain reaction of immune cells that attacks the primary 
tumor and non-irradiated tumor metastasis.[26] Anti-PDL1 and IMM-101 are such 
a immunotherapy agents which induces the innate and adaptive immune system 
in response to cancer.[27-29] Future studies should focus on systemic treatment 
regimens after chemotherapy and radiotherapy. Immunotherapy could be a fruitful 
adjunct therapy for LAPC, by gaining more systemic control after the initial local and 
systemic control induced by chemotherapy and radiotherapy. 
 The American Society of Clinical Oncology (ASCO) advices that patients with LAPC 
could be considered for surgery after significant response to induction therapy was 
achieved.[19] There is a difficulty in defining dramatic response to induction therapy. 
Studies have shown that restaging CT-scan after neoadjuvant treatment in LAPC have 
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a low accuracy to evaluate local tumor size and vitality.[30, 31] Nonetheless, some 
centers advocate that exploration of LAPC patients without biochemical disease 
progression or progression on imaging should undergo an exploration.[31, 32] 
However, there is no data supporting survival benefit or disadvantage of resection 
after systematic therapy in patients with LAPC. Studies reporting high median OS 
after resection LAPC setting are usually biased by patient selection.[33] Randomized 
studies are needed to predict which LAPC patient could benefit from resection after 
induction therapy. 
 In the end, even though there are some breakthroughs in the treatment of LAPC, 
a multidisciplinary approach is essential to achieve the best care. Pancreatic cancer 
is a systemic disease, and LAPC is no exception in this. Therefore, patients diagnosed 
with LAPC must be reviewed in a multidisciplinary tumor board, taking into account 
the preference of the patient. 
Chapter 8
128
References
1. Network., N.C.C. pancreatic adenocarcinoma (version: 2.2015). 2015 09-06-2015]; Available from: http://
www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf.
2. Callery, M.P., et al., Pretreatment assessment of resectable and borderline resectable pancreatic cancer: 
expert consensus statement. Ann Surg Oncol, 2009. 16(7): p. 1727-33.
3. Versteijne, E., et al., Preoperative radiochemotherapy versus immediate surgery for resectable and borderline 
resectable pancreatic cancer (PREOPANC trial): study protocol for a multicentre randomized controlled trial. 
Trials, 2016. 17(1): p. 127.
4. Tempero, M.A., et al., Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in 
Oncology. J Natl Compr Canc Netw, 2017. 15(8): p. 1028-1061.
5. Castillo, C.F.-d. Clinical manifestations, diagnosis, and staging of exocrine pancreatic cancer. 18-03-2019]; 
Available from: www.uptodate.com.
6. Chang, S.T., et al., Natural history of preoperative subcentimeter pulmonary nodules in patients with 
resectable pancreatic adenocarcinoma: a retrospective cohort study. Ann Surg, 2015. 261(5): p. 970-5.
7. Mehtsun, W.T., et al., Are Staging Computed Tomography (CT) Scans of the Chest Necessary in Pancreatic 
Adenocarcinoma? Ann Surg Oncol, 2018. 25(13): p. 3936-3942.
8. Pappas, S.G., et al., Staging chest computed tomography and positron emission tomography in patients 
with pancreatic adenocarcinoma: utility or futility? HPB (Oxford), 2014. 16(1): p. 70-4.
9. Wiener, R.S., et al., Population-based risk for complications after transthoracic needle lung biopsy of a 
pulmonary nodule: an analysis of discharge records. Ann Intern Med, 2011. 155(3): p. 137-44.
10. Liu, R.C. and L.W. Traverso, Diagnostic laparoscopy improves staging of pancreatic cancer deemed locally 
unresectable by computed tomography. Surg Endosc, 2005. 19(5): p. 638-42.
11. Morak, M.J., et al., Staging for locally advanced pancreatic cancer. Eur J Surg Oncol, 2009. 35(9): p. 963-8.
12. Ta, R., et al., The Role of Staging Laparoscopy in Resectable and Borderline Resectable Pancreatic Cancer: A 
Systematic Review and Meta-Analysis. Dig Surg, 2019. 36(3): p. 251-260.
13. Conroy, T., et al., FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med, 2011. 
364(19): p. 1817-25.
14. Suker, M., et al., FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level 
meta-analysis. Lancet Oncol, 2016. 17(6): p. 801-810.
15. Janssen, Q.P., et al., Neoadjuvant FOLFIRINOX in patients with borderline resectable pancreatic cancer: a 
systematic review and patient-level meta-analysis. J Natl Cancer Inst, 2019.
16. Suker, M., et al., FOLFIRINOX and radiotherapy for locally advanced pancreatic cancer: A cohort study. J Surg 
Oncol, 2018.
17. Williet, N., et al., Intensification of induction chemotherapy before consolidation chemoradiotherapy 
improves progression-free survival and time without treatment in patients with locally advanced pancreatic 
cancers. Oncotarget, 2018. 9(62): p. 31999-32009.
18. Gourgou-Bourgade, S., et al., Impact of FOLFIRINOX compared with gemcitabine on quality of life in patients 
with metastatic pancreatic cancer: results from the PRODIGE 4/ACCORD 11 randomized trial. J Clin Oncol, 
2013. 31(1): p. 23-9.
19. Balaban, E.P., et al., Locally Advanced, Unresectable Pancreatic Cancer: American Society of Clinical Oncology 
Clinical Practice Guideline. J Clin Oncol, 2016. 34(22): p. 2654-68.
20. Trakul, N., A.C. Koong, and D.T. Chang, Stereotactic body radiotherapy in the treatment of pancreatic 
cancer. Semin Radiat Oncol, 2014. 24(2): p. 140-7.
21. Goldsmith, C., et al., Dose-Volume Histogram Analysis of Stereotactic Body Radiotherapy Treatment of 
Pancreatic Cancer: A Focus on Duodenal Dose Constraints. Semin Radiat Oncol, 2016. 26(2): p. 149-56.
22. Tsang, E.S., et al., Outcomes and Characteristics of Patients Receiving Second-line Therapy for Advanced 
Pancreatic Cancer. Am J Clin Oncol, 2019. 42(2): p. 196-201.
8129
23. Gandhi, S.J., et al., Awakening the immune system with radiation: Optimal dose and fractionation. Cancer 
Lett, 2015. 368(2): p. 185-90.
24. Formenti, S.C. and S. Demaria, Radiation therapy to convert the tumor into an in situ vaccine. Int J Radiat 
Oncol Biol Phys, 2012. 84(4): p. 879-80.
25. Brix, N., et al., Abscopal, immunological effects of radiotherapy: Narrowing the gap between clinical and 
preclinical experiences. Immunol Rev, 2017. 280(1): p. 249-279.
26. Ngwa, W., et al., Using immunotherapy to boost the abscopal effect. Nat Rev Cancer, 2018. 18(5): p. 313-
322.
27. Banerjee, K., et al., Emerging trends in the immunotherapy of pancreatic cancer. Cancer Lett, 2018. 417: p. 
35-46.
28. Cheung, P.F., M. Lutz, and J.T. Siveke, Immunotherapy and Combination Strategies in Pancreatic Cancer: 
Current Status and Emerging Trends. Oncol Res Treat, 2018. 41(5): p. 286-290.
29. Dalgleish, A.G., et al., Randomised, open-label, phase II study of gemcitabine with and without IMM-101 for 
advanced pancreatic cancer. Br J Cancer, 2016. 115(9): p. e16.
30. Ferrone, C.R., et al., Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for 
locally advanced and borderline resectable pancreatic cancer. Ann Surg, 2015. 261(1): p. 12-7.
31. Hackert, T., et al., Locally Advanced Pancreatic Cancer: Neoadjuvant Therapy With Folfirinox Results in 
Resectability in 60% of the Patients. Ann Surg, 2016. 264(3): p. 457-63.
32. Michelakos, T., et al., Predictors of Resectability and Survival in Patients With Borderline and Locally 
Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX. Ann Surg, 2019. 
269(4): p. 733-740.
33. Godhi, S.A., et al., “Radiological and Surgical Implications of Neoadjuvant Treatment With FOLFIRINOX for 
Locally Advanced and Borderline Resectable Pancreatic Cancer.”. Ann Surg, 2017. 265(6): p. E73.
Appendices
130
9131
Appendices
Contributing authors 
About the author
PhD portfolio
Other publications
Dankwoord
Appendices
132
Contributing authors
Prof. dr. C.H.J van Eijck 
Department of Surgery, Erasmus MC University 
Medical Center, Rotterdam, The Netherlands
Dr. B. Groot Koerkamp
Department of Surgery, Erasmus MC University 
Medical Center, Rotterdam, The Netherlands
Dr. J.J. Nuyttens
Department of Radiotherapy, Erasmus MC 
University Medical Center, Rotterdam, The 
Netherlands 
Dr. F.A.L.M. Eskens
Department of Medical Oncology, Erasmus 
MC University Medical Center, Rotterdam, The 
Netherlands 
Dr. M.Y.V. Homs
Department of Medical Oncology, Erasmus 
MC University Medical Center, Rotterdam, The 
Netherlands 
Dr. R.S. Dwarkasing
Department of Radiology, Erasmus MC 
University Medical Center, Rotterdam, The 
Netherlands 
Dr. P.P. Coene
Department of Surgery, Maasstad Hospital, 
Rotterdam, The Netherlands
Dr. E. van der Harst
Department of Surgery, Maasstad Hospital, 
Rotterdam, The Netherlands
Dr. B.A. Bonsing
Department of Surgery, Leiden University 
Medical Center, Leiden, The Netherlands
Dr. A.L. Vahrmeijer
Department of Surgery, Leiden University 
Medical Center, Leiden, The Netherlands
Dr. J.S.D. Mieog
Department of Surgery, Leiden University 
Medical Center, Leiden, The Netherlands
Dr. RJ. Swijnenburg
Department of Surgery, Leiden University 
Medical Center, Leiden, The Netherlands
Dr. D. Roos 
Department of Surgery, Reinier de Graaf 
Group, Delft, The Netherlands
Dhr. B.R. Beumer
Department of Surgery, Erasmus MC, 
University Medical Centre, Rotterdam,  
The Netherlands
Dr. E. Sadot
Department of Surgery, Memorial Sloan 
Kettering Cancer Center, New York, NY, USA
Dr. L. Marthey 
Department of Hepatogastroenterology, 
Antoine Beclère Hospital, Assistance publique-
Hôpitaux de Paris (AP-HP), Paris Sud University, 
Clamart, France
Dr. J.E. Faris MD
Department of Hematology/Oncology, 
Massachusetts General Hospital, Boston, 
 MA, USA
9133
Dr. E.A. Mellon 
Department of Radiation Oncology, H. Lee 
Moffitt Cancer Center & Research Institute, 
Tampa, FL, USA
Dr. B. El-Rayes
Department of Hematology and Medical 
Oncology, Emory University, Atlanta, GA, USA
Dr. A. Wang-Gillam
Department of Medicine, Washington University 
School of Medicine, Saint Louis, MO, USA
Dr. J. Lacy
Department of Medicine, Yale Cancer Center,  
Yale School of Medicine, New Haven, CT, USA
Dr. P.J. Hosein
Department of Medicine, Division of Medical 
Oncology, University of Kentucky/ Markey 
Cancer Center, Lexington, KY, USA
Dr. S.Y. Moorcraft
Department of Medicine, The Royal Marsden 
NHS Foundation Trust, London & Surrey,  
United Kingdom
Dr. T. Conroy
Department of Medical Oncology, Institut 
de Cancérologie de Lorraine and Lorraine 
University, 54519 Vandoeuvre-lès-Nancy Cedex, 
France
Dr. F. Hohla
Department of Hematology, Medical 
Oncology, Hemostasis, Rheumatology and 
Infectious Diseases, Paracelsus Medical 
University of Salzburg, Salzburg, Austria
Dr. P. Allen
Department of Surgery, Memorial Sloan 
Kettering Cancer Center, New York, NY, USA
Dr. J. Taieb
Department of Gastroenterology and 
Digestive Oncology, Georges Pompidou 
European Hospital, Assistance publique-
Hôpitaux de Paris (AP-HP), Sorbonne Paris Cité, 
Paris Descartes University, Cancer Research 
Personalized Medicine (CARPEM), Paris, France
Dr. T.S. Hong
Department of Hematology/Oncology, 
Massachusetts General Hospital, Boston,  
MA, USA
Dr. R. Shridhar
Department of Radiation Oncology, Florida 
Hospital Cancer Institute, Orlando, FL, USA
Dr. I. Chau
Department of Medicine, The Royal Marsden 
NHS Foundation Trust, London & Surrey, 
United Kingdom
Dr. B.C.M Haberkorn
Department of Medical Oncology, Maasstad 
Hospital, Rotterdam, The Netherlands
Appendices
134
9135
About the author
Mustafa Suker was born on the 17th of October 1988 in 
Baghdad, Iraq. At the age of 8 years, he came together 
with his parents and sister to the Netherlands. He 
graduated from Gymnasium in Venray, the Netherlands 
in 2007. In the same year, he was accepted for medical 
school by decentralized selection at Erasmus University 
in Rotterdam. During his study, he developed interest 
for surgery and science, which resulted in research 
projects in pancreatic surgery under supervision of 
prof. dr. C.H.J. van Eijck. After graduating from medical school in 2014, he was offered 
an PhD program under the same professor and co-promoter dr. B. Grootkoerkamp, 
which has led to this thesis. In 2018, he started as resident doctor in the department 
of surgery at Reinier de Graaf Hospital, Delft (supervisor: Dr. M.R. de Vries). Currently, 
he started with his surgical training to become a surgeon at Erasmus Medical Center 
Rotterdam and Amphia Hospital, Breda under supervision of dr. B.P.L. Wijnhoven and 
dr. L. van der Laan. 
Appendices
136
PhD portfolio
Oral presentations (0.5 point/each)
The International Symposium on Intensive Care and Emergecy Medicine 2015 0.5
Measurement of microcirculatory alterations: A consensus meeting 2015 0.5
Nederlandse Chirurgendagen 2016 0.5
Wetenschapsdag Erasmus MC 2016 0.5
DPCG Pancreas Dag 2016 0.5
European Society of Surgical Research 2016 1.0
Pancreas Club 2017 0.5
Wetenschapsdag Erasmus MC 2016 0.5
Pancreas Club 2018 0.5
International Hepato-Pancreato-Biliary Association 2018 1.0
Poster presentations (0.3 point/each)
International Hepato-Pancreato-Biliary Association 2016 0.6
European Pancreas Club 2016 0.3
Pancreas Club 2017 0.9
Conferences (0.3 point/day)
Nederlandse Chirurgendagen 2014 - 2017 1.0
International Hepato-Pancreato-Biliary Association 2016, 2018 1.0
Pancreas Club 2017 - 2018 0.9
General Courses 
SPSS Statistics 2014 0.5
Good Clinical Practice 2014 0.3
CPO-course (Patient Oriented Research: design, conductance, analysis and 
clinical implications)
2015 0.3
BROK (Basic course Rules and Organization for Clinical researchers) 2015 1.5
Survival Analysis Statistics 2015 0.5
Research Integrity Course 2015 0.3
OpenClinica Course 2016 0.3
Advanced Trauma Life Support (ATLS) 2017 2.0
Reregistration BROK Course 2018 0.5
ESSO-EYSAC Surgical Anatomy Course on Pancreatic Cancer 2019 1.0
9137
Teaching activities 
First aid exams 2014 - 2018 1.0
RISK Education Interns 2015 - 2018 1.0
Minor Gastroenterology 2015 0.3
Tutor first year medical students 2016 1.0
Orginasator Surgical Journal Club of Clinical Oncology 2016 - 2018 1.0
Supervising Master Student B.R. Beumer (Erasmus MC) 2016 - 2017 1.0
Masterclass Verpleegkundigen & Verzorgenden Nederland Jaarcongres 2017 1.0
Appendices
138
Other publications
Journal publications
Aziz MH, Sideras K, Aziz NA, Mauff K, Haen R, Roos D, Saida L, Suker M, van der Harst E, Mieog JS, Bonsing BA, 
Klaver Y, Koerkamp BG, van Eijck CH.
 The Systemic-Immune-Inflammation Index Independently Predicts Survival and Recurrence in 
Resectable Pancreatic Cancer and its Prognostic Value Depends on Bilirubin Levels: A Retrospective 
Multicenter Cohort Study.
 Ann Surg. 2019 Jul;270(1):139-146.
Janssen QP, Buettner S, Suker M, Beumer BR, Addeo P, Bachellier P, Bahary N, Bekaii-Saab T, Bali MA, Besselink 
MG, Boone BA, Chau I, Clarke S, Dillhoff M, El-Rayes BF, Frakes JM, Grose D, Hosein PJ, Jamieson NB, 
Javed AA, Khan K, Kim KP, Kim SC, Kim SS, Ko AH, Lacy J, Margonis GA, McCarter MD, McKay CJ, Mellon 
EA, Moorcraft SY, Okada KI, Paniccia A, Parikh PJ, Peters NA, Rabl H, Samra J, Tinchon C, van Tienhoven 
G, van Veldhuisen E, Wang-Gillam A, Weiss MJ, Wilmink JW, Yamaue H, Homs MYV, van Eijck CHJ, Katz 
MHG, Koerkamp BG.
 Neoadjuvant FOLFIRINOX in patients with borderline resectable pancreatic cancer: a systematic review 
and patient-level meta-analysis.
 J Natl Cancer Inst. 2019 May 14. Epub ahead of print. 
Loi M, Magallon-Baro A, Suker M, van Eijck C, Sharma A, Hoogeman M, Nuyttens J.
 Pancreatic cancer treated with SBRT: Effect of anatomical interfraction variations on dose to organs at 
risk.
 Radiother Oncol. 2019 May;134:67-73.
Suker M, Tovar Doncel MS, Pinto Lima AA, Ince C, van Eijck CHJ.
 Sublingual microcirculation in pancreatico-biliary surgery: An observational study.
 Clin Hemorheol Microcirc. 2019 Mar 2. Epub ahead of print.
de Rooij T, van Hilst J, van Santvoort H, Boerma D, van den Boezem P, Daams F, van Dam R, Dejong C, van Duyn 
E, Dijkgraaf M, van Eijck C, Festen S, Gerhards M, Groot Koerkamp B, de Hingh I, Kazemier G, Klaase J, de 
Kleine R, van Laarhoven C, Luyer M, Patijn G, Steenvoorde P, Suker M, Abu Hilal M, Busch O, Besselink M; 
Dutch Pancreatic Cancer Group.
 Minimally Invasive Versus Open Distal Pancreatectomy (LEOPARD): A Multicenter Patient-blinded 
Randomized Controlled Trial
 Ann Surg. 2019 Jan;269(1):2-9.
Suker M, Harki J, Tovar-Doncel MS, van Dijk LJD, van Noord D, van Eijck CHJ, Bruno MJ, Kuipers EJ, Ince C
 Patients with chronic mesenteric ischemia have an altered sublingual microcirculation
 Clin Exp Gastroenterol. 2018 Oct 18;11:405-414.
9139
Strijker M, Gerritsen A, van Hilst J, Bijlsma MF, Bonsing BA, Brosens LA, Bruno MJ, van Dam RM, Dijk F, van 
Eijck CH, Farina Sarasqueta A, Fockens P, Gerhards MF, Groot Koerkamp B, van der Harst E, de Hingh IH, 
van Hooft JE, Huysentruyt CJ, Kazemier G, Klaase JM, van Laarhoven CJ, van Laarhoven HW, Liem MS, 
de Meijer VE, van Rijssen LB, van Santvoort HC, Suker M, Verhagen JH, Verheij J, Verspaget HW, Wennink 
RA, Wilmink JW, Molenaar IQ, Boermeester MA, Busch OR, Besselink MG; Dutch Pancreatitis Study Group 
and Dutch Pancreatic Cancer Group.
 The Dutch Pancreas Biobank Within the Parelsnoer Institute: A Nationwide Biobank of Pancreatic and 
Periampullary Diseases.
 Pancreas. 2018 Apr;47(4):495-501.
van Vugt JLA, Buettner S, Levolger S, Coebergh van den Braak RRJ, Suker M, Gaspersz MP, de Bruin RWF, 
Verhoef C, van Eijck CHC, Bossche N, Groot Koerkamp B, IJzermans JNM.
 Low skeletal muscle mass is associated with increased hospital expenditure in patients undergoing 
cancer surgery of the alimentary tract.
 PLoS One. 2017 Oct 31;12(10):e0186547.
Versteijne E, Lens E, van der Horst A, Bel A, Visser J, Punt CJA, Suker M, van Eijck CHJ, van Tienhoven G. 
 Quality Assurance of the Preopanc Trial (2012-003181-40) for Preoperative Radiochemotherapy in 
Pancreatic Cancer : The Dummy Run
 Strahlenther Onkol. 2017 Aug;193(8):630-638.
Suker M, Bruemer BR, van Eijck CHJ, Groot Koerkamp B.
 FOLFIRINOX voor lokaal irresectabel pancreascarcinoom: een systematische review en meta-analyse op 
individueel patiëntenniveau.
 Nederlandse Tijdschrift Oncologie 2017; 14;101-13.
Suker M, Doukas M, van Eijck CHJ, Biermann K. 
 Pancreatic Duct Obstruction in a Middle-Aged Woman: A Case Report
 Journal of Pancreatic Cancer. February 2017, 3(1): 13-14.
Suker M, van Eijck CHJ, Biermann K, Doukas M.
 A Rare Tumor in the Common Bile Duct: A Case Report
 Journal of Pancreatic Cancer. February 2017, 3(1): 10-12.
Versteijne E, van Eijck CH, Punt CJ, Suker M, Zwinderman AH, Dohmen MA, Groothuis KB, Busch OR, Besselink 
MG, de Hingh IH, Ten Tije AJ, Patijn GA, Bonsing BA, de Vos-Geelen J, Klaase JM, Festen S, Boerma D, 
Erdmann JI, Molenaar IQ, van der Harst E, van der Kolk MB, Rasch CR, van Tienhoven G, Dutch Pancreatic 
Cancer G. 
 Preoperative Radiochemotherapy Versus Immediate Surgery for Resectable and Borderline Resectable 
Pancreatic Cancer (Preopanc Trial): Study Protocol for a Multicentre Randomized Controlled Trial. 
 Trials. 2016;17(1):127.
Nonnekens J, van Kranenburg M, Beerens CE, Suker M, Doukas M, van Eijck CH, de Jong M, van Gent DC. 
 Potentiation of Peptide Receptor Radionuclide Therapy by the Parp Inhibitor Olaparib. 
 Theranostics. 2016;6(11):1821-32.
Suker M, Ten Berge JC, , Bruno MJ, Poley JW, Dwarkasing R, Biermann K, van Eijck CH. 
 Are a Double Duct Sign or Endoscopic Biopsies Reliable Predictors of Malignancy in Periampullary 
Lesions. 
 Dig Surg. 2015;32(4):306-11.
Appendices
140
Book chapter publications
Suker M, Ince C
 Monitoring the microcirculation
 In book: Svensen CH, editor. Fluid therapy for the surgical patient: CRC press 2018. p.95-109.
Suker M, van Eijck C
 Pancreatic resection after neoadjuvant treatment
 In book: Springer International Publishing; 2017. p. 221-229.
Suker M, Ince C, van Eijck C. 
 Critical Illness is Top Sport.
 In book: Vincent J-L, editor. Annual Update in Intensive Care and Emergency Medicine 2015: Springer 
International Publishing; 2015. p. 519-29.
9141
Appendices
142
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
9143
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendices
144
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
9145
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
